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SYNTHESIS, CHARACTERIZATION, AND CATALYTIC AND BIOLOGICAL

ACTIVITIES OF A MIXED-LIGAND COBALT(II)
BIPYRIDYL/DIPHENYLAZODIOXIDE COMPLEX

KYLIN A. EMHOFF

ABSTRACT
Transition metal complexes have immense importance in the pharmaceutical
industry. These types of complexes can be useful catalysts in the synthesis of medicinal
compounds and can act as anticancer drugs. In these pharmaceutical applications, 1st-row

transition metal-containing complexes offer certain advantages compared to their 2nd and

3rd-row transition metal counterparts. Our motivation was to investigate pharmaceutical

applications of transition metal complexes containing both a 1st-row transition metal and
unusual ligands to expand the knowledge of a class of complexes that could potentially be

beneficial in the pharmaceutical industry. A class of rare ligands that piqued our interest

was that of the diaryl azodioxides, cis-Ar(O)NN(O)Ar, which belong to the wider class of
organic derivatives of nitric oxide (NO). Our synthesis and pharmaceutical applications of
the azodioxide complex salt [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 have been able to

significantly expand the knowledge of azodioxide complexes by displaying an unusual
trigonal prismatic coordination geometry for cobalt(II) with only bidentate ligands,

showing evidence of ligand-based redox activity, acting as an active catalyst in allylic
amination/C-C double-bond transposition reactions, and selectively inducing apoptosis in
SK-HEP-1 human liver adenocarcinoma cells. Importantly, catalytic and biological studies

of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 are ongoing, and focused on its potential for use in
the pharmaceutical industry as a drug or catalyst for drug synthesis. Future work will

vi

involve

comparing

the

catalytic

and

biological

activities

of

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 with other azodioxide complexes prepared by our
group to identify structure-activity relationships and inform the design of more efficient

catalysts and anti-cancer, pro-apoptotic agents.
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CHAPTER I

INTRODUCTION

1.1 Transition Metal Complexes as Catalysts in the Pharmaceutical Industry
Transition metal complexes have immense importance in the pharmaceutical
industry. In particular, some transition metal complexes can be useful catalysts for the

synthesis of drugs or other medically relevant compounds. The benefits of catalysis include

a smaller number of synthetic steps, a reduction in the amount of waste produced, and a
decrease in both reaction times and the amounts of reagents used. It has been estimated that

about 90% of commercially-derived pharmaceuticals in the industry are produced using
catalysis, and catalysis allows a pharmaceutical company to strengthen its product worth
while reducing the carbon footprint of its processes. Processes that involve catalysis by
transition metal complexes have been applied widely in the pharmaceutical industry, for

the past 30 years in particular. Examples of transition metal-catalyzed reactions in the
pharmaceutical industry include (but are not limited to) asymmetric hydrogenation, alkene

metathesis, carbon-carbon (C-C) or carbon-heteroatom (C-X, where “X” is a heteroatom)
cross-coupling reactions, and allylic amination. Specifically, transition metal-catalyzed

processes have been applied in both discovery syntheses and large-scale active
pharmaceutical ingredient (API) syntheses. Transition metal catalysts allow for the highly

1

efficient preparation of target molecules by imparting chemo-, regio-, and stereoselectivity

to reactions.1 An especially important distinguishing feature of transition metal catalysts in
the pharmaceutical industry is their ability to impart enantioselectivity, which involves the

selective synthesis of one enantiomer of a chiral product from achiral reagents.2 It is very

important to note that often only one of a drug’s enantiomers is considered safe and
effective.

1.1.1 Use of 1st-Row Transition Metals as Catalysts
Although most transition metal-catalyzed processes in the pharmaceutical industry

involve the use of 2nd- or 3rd-row transition metals such as palladium, ruthenium, and
iridium, there are important advantages to utilizing 1st-row transition metals as catalysts.

Firstly, 1st-row transition metal catalysts are cheaper to use compared to 2nd and 3rd-row
transition metal catalysts, making 1st-row transition metal catalysts more cost-effective.
Moreover, 1st-row transition metals are more Earth-abundant than 2nd- or 3rd-row transition

metals, meaning that the use of 1st-row transition metals are more environmentally
friendly.3 An additional advantage of employing 1st-row transition metal catalysts is their

ability to undergo oxidation state changes by one unit, which can be useful in the catalysis
of radical reactions. In contrast, 2nd- and 3rd-row transition metal catalysts more often
undergo changes of oxidation state by two units.

The use of 1st-row transition metal catalysts has thus far shown promise and
potential in the pharmaceutical industry. For example, Abbott Laboratories has shown

copper(I) chloride (CuCl) to be an active catalyst in a C-N cross-coupling reaction
involved as a key step in the kilogram-scale synthesis of an H3 receptor antagonist used to

treat attention deficit hyperactivity disorder (ADHD).4 Additionally, the State Key

2

Laboratory of Drug Research in China has shown that the nickel complex NiCl2(dppp)

(where dppp = 1,3-bis(diphenylphosphino)propane) is a useful catalyst in a Kumada-

Corriu coupling reaction that is considered a key step in the overall synthesis of atazanavir,5

a drug used to treat HIV/AIDS that is on the World Health Organization’s (WHO) List of
Essential Medicines as of 2019.6 The Chirik group, in collaboration with the
pharmaceutical company Merck, has demonstrated the ability of the simple cobalt

compound CoCh-6H2O and the chiral phosphine ligand (Ph-BPE-R,R) to form an in situ
catalyst that has shown to be enantioselective in the asymmetric hydrogenation of an

enamide that yields the anticonvulsant levetiracetam in 98.2% ee (enantiomeric excess).3,7
The iron complex Fe(acac)2 (where acac = acetylacetonate) has been reported as an
efficient stereoselective catalyst in a C-C cross-coupling reaction that is a key step in the

synthesis of sitagliptin,8 a medication used to treat type 2 diabetes. Lastly, the iron complex
Fe(CO)3{ n4-(CH2)4(SiMe3)2C5O} has proven to be an active catalyst in a nucleophilic

allylic substitution reaction that yields the drug cinnarizine,9,10 which is an antihistamine

used to treat motion sickness.

1.2 Transition Metal Complexes in Medicine
In addition to the use of transition metal complexes as catalysts in the

pharmaceutical industry, transition metal complexes have also shown the ability to act as
pharmaceuticals themselves. Although most currently approved drugs are organic
molecules,11 bioinorganic chemists have been increasingly interested in the potential of
transition metal complexes to act as drugs.12 Unlike purely organic molecules, transition

metal complexes have unique features that make them have a great deal of pharmaceutical
potential, especially as anti-cancer therapeutics. These features include the ability of

3

transition metal ions to be involved in biological redox reactions, the possibility of
transition metals to display a wide range of coordination geometries and coordination

numbers, the varied reactivity that transition metal compounds display toward organic

substrates,12 and the potential for transition metal complexes to demonstrate
stereoisomerism at their metal centers.13 Because of these unique features, transition metal
containing drugs can display mechanisms of action that are vastly different from organic
molecules, ultimately leading to different types of transport pathways and novel drug

targets. Therefore, drugs containing transition metals have the potential to overcome

resistances to organic drugs developed by pathogens or cancer cells.11,14
1.2.1 Use of 1st-Row Transition Metals as Drugs
Most approved or promising transition metal-containing drugs contain 2nd- or 3rd-

row transition metals, with perhaps the most important example being the platinumcontaining anticancer drug cisplatin, cis-Pt(NH3)2Cl2.15 However, there has recently been
an increasing interest in developing 1st-row transition metal-containing pharmaceuticals,

due to their greater cost-effectiveness and Earth-abundance. Additionally, 1st-row
transition metals are generally less toxic than 2nd- and 3rd-row transition metals, although

there are some notable exceptions to this claim: some nickel compounds, the most
infamous example being Ni(CO)4, and many chromium(VI) compounds are toxic and
carcinogenic, while many silver and gold compounds are considered fairly harmless.16

An example of a promising drug candidate that contains a 1st-row transition metal
is the vanadium complex [bis(ethylmaltolato)oxovanadium(IV)] (BEOV). Orvig and

coworkers have been able to show the potential of this complex in the treatment of diabetes,
especially type 2,11,17,18 by successfully completing a small phase II clinical trial in which

4

fasting blood glucose and HbA1c (glycated hemoglobin) levels were shown to be overall
reduced in a range from 10% to 40% in 5 out of 7 type 2 diabetes patients.18 Furthermore,

hydroxycobalamin and cyanocobalamin, which are two forms of vitamin B12 (a vitamin
that is essential in the formation of red blood cells, DNA synthesis, metabolism of cells,

and nerve function19) and which both contain cobalt, are well known and widely used in

medicine. More specifically, hydroxycobalamin, which is on the WHO List of Essential

Medicines as of 2019,6 is known for treating vitamin B12 deficiency11 and cyanide
poisoning,20 whereas cyanocobalamin treats only vitamin B12 deficiency.11 Another

example of a cobalt-containing complex that has shown pharmaceutical potential is
Doxovir,

also

known

as

CTC-96

or

[bis(2-

methylimidazole)[bis(acetylacetone)(ethylenediimine)]cobalt(III). Doxovir has shown

promising antiviral activity by successfully completing phase II clinical trials for the
treatment of the herpes simplex virus.11,21 Moreover, doxovir has shown potential antiviral

activity in the treatment of ophthalmic herpetic keratitis22 and adenoviral conjunctivitis23
(viral eye infections) by successfully completing phase I clinical trials.11 The iron complex

7-chloro-N-(2-((dimethylamino)methyl)ferrocenyl)quinolin-4-amine, or ferroquine, has

proven to be a promising organometallic drug candidate in the treatment of malaria.11,24,25
Specifically, ferroquine has shown antimalarial activity at concentrations in the nanomolar
range against both chloroquine-susceptible and chloroquine-resistant Plasmodium
falciparum, which is the parasite that causes the deadliest form of malaria. (Note:

chloroquine is a purely organic drug used to treat malaria.) Ferroquine as an antimalarial

agent is currently in the process of undergoing phase II clinical trials.25 Lastly, the ironcontaining drug sodium nitroprusside, Na2[Fe(CN)5NO], is already a widely used drug in
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the treatment of hypertension11,26 and is on the WHO List of Essential Medicines as of

2019.6 The medicinal use of sodium nitroprusside is discussed further in Section 1.4.2.

1.3 Motivation of Research Project
We were motivated to investigate the potential pharmaceutical applications of

novel 1st-row transition metal complexes, in particular the medicinal potential of transition
metal complexes containing both a 1st-row transition metal and unusual ligands that have

not previously been widely studied. In this way, we could expand the knowledge of a class

of complexes that could potentially be beneficial in the pharmaceutical industry. A class of

rare ligands that piqued our interest is that of the diaryl azodioxides, cis-Ar(O)NN(O)Ar,
which belong to the wider class of organic derivatives of nitric oxide (NO).

1.4 Nitric Oxide (NO)
1.4.1 NO in the Immune and Nervous Systems
Nitric oxide (NO) is a diatomic free radical with several roles in the human body.

Firstly, NO has important roles in the immune and nervous systems. In the immune system,
NO demonstrates antitumor, antimicrobial, and cytotoxic activity, which involves the

generation of reactive oxygen species (ROS), which then lead to inactivation of enzymes
and the modification of proteins, ultimately killing pathogens such as bacteria, fungi, and

viruses, as well as tumor cells. In the nervous system, NO acts as a neurotransmitter by

regulating the intake of nutrients, perception of pain, and blood flow to the brain.27
1.4.2 NO in Vasodilation
A particularly important physiological role of NO is its ability to induce
vasodilation, a process that involves the widening of blood vessels, thus lowering blood

pressure and increasing blood flow. Vasodilation occurs when NO activates the heme
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enzyme soluble guanylate cyclase (sGC), which is responsible for the catalytic
transformation of guanosine triphosphate (GTP) to cyclic guanosine monophosphate

(cGMP),28,29 and the formation of cGMP as a secondary messenger molecule signals the

smooth muscle in blood vessels to relax, which leads to a decrease in blood pressure.
Without NO, sGC would be inactive and the formation of cGMP would not occur. The role

of NO as a vasodilator was discovered by Robert Furchgott, Louis Ignarro, and Ferid

Murad, who shared the Nobel Prize in Physiology or Medicine in 1998 for this discovery.28
The role of NO in vasodilation has been widely exploited in medicine. The organic

drugs amyl nitrite and nitroglycerin are examples of vasodilators that are known for treating
angina in people who have coronary artery disease. Amyl nitrite and nitroglycerin release
NO into the body when reacting with physiological thiols.28 In addition to amyl nitrite and
nitroglycerin, the iron-containing drug sodium nitroprusside, Na2[Fe(CN)5NO], which was

briefly mentioned in Section 1.2.1, also acts as an antihypertensive drug.13,26,28 However,

unlike amyl nitrite and nitroglycerin, sodium nitroprusside releases NO gradually into the
body on its own.28 Sodium nitroprusside can also be taken by surgical patients in order to

reduce bleeding during surgery.30 Importantly, sodium nitroprusside and nitroglycerin are
on the WHO List of Essential Medicines as of 2019.6 Another important vasodilator worth

mentioning is sildenafil (Viagra). Unlike the other vasodilators mentioned thus far,
sildenafil does not release NO into the body, either directly or indirectly. Rather, sildenafil

acts as a vasodilator by inhibiting cGMP degradation and thus indirectly increasing the
activity of the NO generated by the body.31

7

1.4.3 NO as a Ligand in Coordination Chemistry

The involvement of NO in vasodilation is due to the ability of NO to bind to
transition metals as a ligand. In particular, NO binds to the heme iron center in sGC, which

causes the histidine ligand in the axial position trans to NO to dissociate, hence leading to

a change in the conformation of sGC. This altered conformation is what activates sGC to
catalyze cGMP formation.29,32 When NO is bound to transition metals, it is referred to as

the nitrosyl ligand and can coordinate to transition metals in either a linear or bent fashion.

When NO coordinates to a transition metal in the linear binding mode, it acts as a threeelectron donor in its neutral form or as a two-electron donor in the ionic form NO+

(isoelectronic with the well-known n-acceptor ligands CO and CN). On the other hand,
when NO coordinates to a transition metal in the bent binding mode, it acts as a oneelectron donor in its neutral form or as a two-electron donor in the ionic form NO-.32,33
These linear and bent binding modes of the nitrosyl ligand to a transition metal are depicted

in Figure 1 (“M” represents a generic transition metal).

Importantly, NO is able to behave as a redox-active ligand in transition metal

complexes, in that the conversion from the linear coordination mode to the bent
coordination mode involves an increase in a metal’s oxidation state by two and a decrease
in its overall electron count by two, along with the opening of a binding site. In fact, some
transition metal complexes containing the NO ligand in the linear geometry can exist in

equilibrium with those containing the NO ligand in the bent geometry. This usually
happens when the energy difference between the two binding modes is small and can be

thought of as an electron-transfer process from the metal to the NO ligand. Figure 2 shows
a cobalt complex with an NO ligand in the linear geometry in equilibrium with the same
8

complex containing the NO ligand in the bent geometry. This redox-active behavior of NO

has been employed in catalysis.34

Figure 1: Linear and bent modes of coordination of NO ligand.

Figure 2: Conversion from linear NO to bent NO in a transition metal complex.
1.5 N,N‘-Azodioxides
Though the coordination chemistry of NO is well established, there is a comparative
paucity of information regarding the coordination chemistry of organic derivatives of

NO,33,35 particularly the nitrosoarenes (ArNO). (When NO is a substituent in an organic
molecule, it is referred to as the nitroso group.) Nitrosoarenes can undergo dimerization
to form cis- and trans-N,N'-azodioxides as shown in Figure 3. Whether a nitrosoarene
dimerizes or not depends on its aryl group. The aryl group of the nitrosoarene also dictates

whether the dimer will be favored in the cis or the trans form. Monomeric nitrosoarenes
are generally favored in the solution phase, whereas dimeric azodioxides are favored in the
solid phase.33,35
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Figure 3: Dimerization of nitrosoarenes to dimeric NN-azodioxides.

Of the cis- and trans-N,N'-azodioxides that result from dimerization, the cis form
is of particular interest because it can act as a bidentate (two points of attachment) chelating

ligand, forming a five-membered ring with a metal center; such five-membered chelate

rings are frequently especially stable because they have very low ring strain.36 Figure 4
shows how a generic cis-N,N'-azodioxide coordinates to a generic metal (M). In general,

metal complexes with chelating ligands like cis-N,N'-azodioxides are more stable than
metal complexes with monodentate (one point of attachment) ligands like ArNO that bind
to metals through O atoms. The greater stability of metal complexes possessing chelating

ligands can be explained by the thermodynamic and kinetic chelate effects. Regarding

thermodynamics, an increase in entropy occurs when chelating ligands replace similar
monodentate ligands because the total number of molecules increases in such a reaction.

The kinetic chelate effect refers to the fact that as soon as one of the donor atoms of a
chelating ligand binds to a metal, it is likely the other donor atom(s) of the chelating ligand

will rapidly bind to the metal due to their close proximity.36
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Figure 4: cis-N,N'-azodioxide coordinated to a metal.
More specifically, this project concentrates on the coordination chemistry of a

prototypic ligand of the azodioxide group, cis-N,N'-diphenylazodioxide, Ph(O)NN(O)Ph,
which is formed from the dimerization of nitrosobenzene (PhNO); notably, the cis
diastereomer of Ph(O)NN(O)Ph is favored in the solid state.33,37 A plausible explanation

for why Ph(O)NN(O)Ph is favored in the cis form is that this isomer’s polar structure may
lead to the formation of crystals that are more thermodynamically stable due to dipole

dipole attractions between neighboring molecules. In addition to cis-Ph(O)NN(O)Ph

possessing chelating ability, its N-O and N-N bond lengths, which were obtained from its
crystal structure,37 correspond to significant n delocalization. This delocalization is
depicted by the resonance structures in Figure 5 and can be viewed as analogous to that of

the 1,3-butadiene dianion.

O%

,0

N—N
/
\
Ph
Ph

Figure 5: Resonance structures of cis-Ph(O)NN(O)Ph.

1.6 Azodioxide Complexes
Despite the stability of azodioxide complexes suggested by the presence of a
chelating ligand with significant n delocalization, only five crystallographically
11

characterized azodioxide metal complexes have thus far been reported in the literature.
Additionally, spectroscopically characterized azodioxide complexes such as those of the

form MCl4{Ph(O)NN(O)Ph} (M = Sn, Ti),38 [R2Pb{R(O)NN(O)R}](NO3)2 (R = Me, Et),39
and [Me2Sn{Me(O)NN(O)Me}](NO3)240 have been reported, although none of their

crystal structures were determined. It is possible that azodioxide complexes are as rare as

they are because PhNO tends to exist as a dimer in the solid phase but as a monomer in the
solution phase, thus making solution-phase synthesis of complexes of the dimer more

difficult.33,37

1.6.1 Structurally Characterized Azodioxide Complexes Prior to Our Work

Of the five structurally characterized azodioxide complexes reported in the
literature, three of these complexes were reported prior to our work. One of these

complexes

is

the

scandium(III),

(no

d0

valence

d

electrons)

complex41

Sc(OTf)3(H2O)2{Ar(O)NN(O)Ar} (Ar = 2-MeOC6H4 and OTf = OSO2CF3), whose
structure is shown in Figure 6. This scandium azodioxide complex has shown reactivity by
undergoing a reaction with 1,3-cyclohexadiene to yield a hetero-Diels-Alder adduct with
(2-MeOC6H4)NO, which is the monomeric form of its corresponding dimeric azodioxide

ligand. A second azodioxide complex that was reported prior to our work is the calcium(II)
(main group metal) complex salt42 [Ca{Ph(O)NN(O)Ph}(H2O)2(THF)3]I2, whose structure

is shown in Figure 7. To the best of our knowledge, the reactivity of this calcium azodioxide
complex has not been investigated. The last azodioxide complex to mention that was

reported prior to our work is the salt of an iron(II), d6 complex cation with iron(III) complex
anions43 [Fe{Ph(O)NN(O)Ph}3](FeCl4)2, which has been shown to be a competent catalyst

for allylic amination/C-C double-bond transposition reactions of alkenes with
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hydroxylamines.44

Figure 6: Structure of Sc(OTf)3(H2O)2{Ar(O)NN(O)Ar}.

Figure 7: Structure of [Ca{Ph(O)NN(O)Ph}(H2O)2(THF)3]I2.
The transition metal complex salt [Fe{Ph(O)NN(O)Ph}3](FeCl4)2 was of particular
interest to our group because, prior to our work, it was the only crystallographically

characterized, non-d azodioxide transition metal complex salt reported in the literature.

The synthesis of [Fe{Ph(O)NN(O)Ph}3](FeCl4)2 was conducted by Nicholas and
coworkers43 and is shown in Figure 8a. It is evident that the reaction depicted in Figure 8a
is not balanced, as this reaction yields a mixture of byproducts in addition to the complex

salt. Given the fact that the complex salt contains an Fe(II) complex cation and an Fe(III)
complex anion, it is very likely that PhNO or its dimeric form acts as an oxidizing agent,

oxidizing some Fe(II) in FeCl2 to Fe(III). This is supported by the GC-MS detection of the
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reduced organic products azoxybenzene, Ph(O)NNPh, and azobenzene, PhNNPh, in the

reaction

mixture.

Moreover,

while

conducting

the

synthesis

of

[Fe{Ph(O)NN(O)Ph}3](FeCl4)2, Nicholas’ group also observed a rust-brown precipitate,
which is likely iron(III) oxide (Fe2O3).43 A proposed balanced reaction equation for the

synthesis of [Fe{Ph(O)NN(O)Ph}3](FeCl4)2 in which PhNO or its dimer is undergoing only

partial deoxygenation is depicted in Figure 8b. (A similar reaction equation could be

written for the complete deoxygenation of PhNO or its dimer to form azobenzene.)
Furthermore, the six-coordinate Fe(II) complex cation shown in Figures 8a and 8b displays

a trigonal prismatic coordination geometry (much less common than an octahedral
geometry for six-coordinate metal complexes) and has N-O and N-N bond lengths that are
similar to those in cis-Ph(O)NN(O)Ph and that suggest that substantial n delocalization is
preserved upon coordination.43

CHCI3

Figure 8a: Synthesis of [Fe{Ph(O)NN(O)Ph}3](FeCl4)2.

Figure 8b: Proposed balanced reaction equation for the synthesis of
[Fe{Ph(O)NN(O)Ph}3](FeCl4)2.
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1.6.2 Homoleptic Cobalt(II) Azodioxide Complex in the Boyd Group

In addition to the three azodioxide complexes that have been structurally
characterized prior to our group’s work, I (as an undergraduate student) assisted a former
graduate student in the Boyd research group, Dr. Lakshmi Balaraman (Ph.D. May 2019),
on the preparation of the novel, homoleptic (only one type of ligand) cobalt(II) azodioxide
complex [Co{Ph(O)NN(O)Ph}4](PF6)2, which was the first azodioxide complex

crystallographically characterized by our group. The synthesis and characterization of

[Co{Ph(O)NN(O)Ph}4](PF6)2 has been published in ACS Omega.45 The synthesis of
[Co{Ph(O)NN(O)Ph}4](PF6)2 is shown in Figure 9.

It is important to note that [Co{Ph(O)NN(O)Ph}4]2+ has an unusually high
coordination number of eight with a distorted tetragonal coordination geometry. Most
Co(II) complexes are either tetrahedral or octahedral.46 There are only a few examples in

the literature of eight-coordinate monometallic Co(II) complexes: [(Ph4As)2[Co(NO3)4], in

which [Co(NO3)4]2- is an eight-coordinate dodecahedral complex anion; [CoL2](ClO4)2 (L
= 2,11-diaza[3.3.](2,6)pyridinophane), which is another example of a Co(II)

eight

coordinate dodecahedral species; and the crown ether complex cations [Co(12-crown-

4)2]2+ and [Co(benzo-12-crown-4)2]2+, which are eight-coordinate with a square
antiprismatic coordination geometry.47
Furthermore, like the N-O and N-N bond lengths in free (uncoordinated) cisPh(O)NN(O)Ph

and

in

[Fe{Ph(O)NN(O)Ph}3](FeCl4)2,

[Co{Ph(O)NN(O)Ph}4](PF6)2 are indicative of n delocalization.45
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Figure 9: Synthesis of [Co{Ph(O)NN(O)Ph}4](PF6)2.
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CHAPTER II

REDOX-ACTIVE LIGANDS

2.1 Introduction
Ligands with substantial n delocalization are potentially redox active. A redox

active ligand is one for which more than one assignment of charge is plausible. Therefore,
there is ambiguity in assigning the oxidation state of a metal center in complexes bearing

these types of ligands, as it depends on the charge assigned to the redox-active ligand(s).48

Transition metal complexes containing redox-active ligands are widely employed in the
catalysis of organic reactions.49

2.2 2,2‘-Bipyridyl (bpy)
An example of a well-known class of redox-active ligands is that of the aromatic

diimines, which are bidentate chelating ligands. An especially important aromatic diimine
is 2,2'-bipyridyl (bpy). Many complexes containing this ligand are known to be

photochemically active, with an electronic excited state accessible through metal-to-ligand
charge transfer (MLCT).50 This type of charge transfer involves electron transfer to a

primarily ligand-based molecular orbital (MO) from a primarily metal d orbital-based MO.
Generally, MLCT is observed in transition metal complexes containing ligands with empty
n antibonding (n*) orbitals that are fairly low in energy.51 Aromatic diimine ligands such
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as bpy possess such low-lying, empty n* orbitals. In addition to a ligand possessing low-

lying n* orbitals, the transition metal in a complex must have a sufficiently low oxidation

number for MLCT to occur. The low oxidation number of the metal would make the energy
gap between the metal d orbitals and the empty low-lying n* ligand orbital small enough

for MLCT to take place.51 Figure 10 shows an example of a ruthenium(II) complex with
three bpy ligands, Ru(bpy)32+, undergoing MLCT. When this complex absorbs photons of

visible light with energy hv, Ru(II) is oxidized to Ru(III), whereas one of the neutral bpy
ligands is reduced to a radical monoanion (bpy’ ").50 In other words, the excited state of this
complex can be represented as (Ru3+)(bpy)2(bpy’ -), as opposed to the ground state of

(Ru2+)(bpy)3. Since Ru(bpy)32+ can be easily excited, it can act as a photosensitizer, and
since the lifetime of its excited state is long (on the order of microseconds),51 that excited

state is able to mediate chemical reactions.50 An important application of Ru(bpy)32+, as
well as related ruthenium complexes with bpy derivatives as ligands, is their use in water

oxidation systems.52 Furthermore, the Yoon group has demonstrated the use of salts of
Ru(bpy)32+ and related cations as active photocatalysts for [2+2] cycloaddition reactions.53

Figure 10: Ru(bpy)32+ undergoing photoinduced MLCT.
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2.3 3,5-Di-tert-butylcatecholate (3,5-DBCat2-)
In addition to the aromatic diimine bpy, the dianion 3,5-di-tert-butylcatecholate
(3,5-DBCat2-) is also a known redox-active ligand.54 Upon one-electron oxidation of this
ligand, the radical monoanion 3,5-di-tert-butylsemiquinone (3,5-DBSQ-) is formed. If a

second one-electron oxidation were to occur, the neutral 3,5-di-tert-butyl-ortho-

benzoquinone would form. These redox states are shown in Figure 11.

3,5-DBCat2-

3,5-DBSQ-

Figure 11: Redox states of 3,5-DBCat.
Solution-phase spectroscopic analysis and magnetic measurements indicated an

equilibrium between the cobalt(III) complex CoIII(3,5-DBCat)(3,5-DBSQ)(bpy), prepared
by Pierpont and coworkers, and its electroisomer (valence tautomer) CoII(3,5DBSQ)2(bpy), which is a cobalt(II) complex, as shown in Figure 12.54 This

electroisomerization equilibrium is a result of ligand-to-metal charge transfer (LMCT).

Unlike MLCT, LMCT involves electron transfer to a primarily metal-based MO from a

primarily ligand-based MO. Frequently, LMCT is observed in transition metal complexes
that contain a transition metal with a high oxidation number, e.g. Mn(VII) in MnO4-, and

ligands that have additional lone pairs of electrons.51 However, the Pierpont group’s
transition metal complex CoIII(3,5-DBCat)(3,5-DBSQ)(bpy) was demonstrated to undergo
LMCT even though Co is only in the +3 oxidation state, which is not exceedingly high for

Co, as the most common oxidation states for Co in its compounds are +2 and +3.55
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Therefore, this result from the Pierpont group shows that a higher-than-usual oxidation

state for a transition metal is not always required for LMCT to occur.54 Moreover, for
LMCT to occur, the nonbonding electrons on the ligands should be fairly high in energy,

while the empty metal d orbitals should be fairly low in energy.51 Referring again to the
electroisomerization equilibrium depicted in Figure 12, the 3,5-DBCat2- ligand in the

CoIII(3,5-DBCat)(3,5-DBSQ)(bpy) complex transfers an electron to the Co(III) center,
hence undergoing LMCT. In this process, 3,5-DBCat2- is oxidized to 3,5-DBSQ-, whereas

Co(III) is reduced to Co(II), yielding the product CoII(3,5-DBSQ)2(bpy).54 One may think
of this electroisomer product as a thermally accessible, low-lying electronic excited state
that is favored at high temperatures. In contrast, UV-visible spectroscopy involves a

molecule being excited via the absorption of light to an electronic excited state that is much
higher in energy (as is commonly observed in the photochemistry of bpy complexes) than
those states that can be significantly populated by heating.56 With the complex CoIII(3,5DBCat)(3,5-DBSQ)(bpy), the Pierpont group had the rare opportunity of investigating
electron transfer between a metal and ligands under the conditions of thermal equilibrium.54

Co^(3,5-DBCat)(3,5-DBSQ)(bpy)

CoII(3,5-DBSQ)2(bpy)

Figure 12: Electroisomerization equilibrium in a Co catecholate/semiquinone complex.
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2.4 2,4-Di-tert-butyl-6-tert-butylamidophenolate (ap2-)
The last important redox-active ligand to be discussed here is 2,4-di-tert-butyl-6tert-butylamidophenolate (ap2-). The Heyduk group has shown this ligand to be useful in
reactions of transition metal complexes that entail changing a ligand’s oxidation state rather

than changing a metal’s oxidation state. More specifically, the Heyduk group has
demonstrated the use of the ap2- ligand to allow for zirconium(IV), d0 complexes to undergo
reactions similar to oxidative addition and reductive elimination, but in which the Zr metal

center remains in the +4 oxidation state during the reactions.57,58 Technically, an oxidative
addition reaction is observed when a molecule of the form X-Y adds to a transition metal

center in order to form two new bonds of the form M-X and M-Y, with the X-Y bond

being cleaved in the process. As a result, the metal’s oxidation number, the total electron
count at the metal, and the coordination number increase by two. Therefore, for an
oxidative addition to occur, the metal ion must have a d electron configuration of at least

d2. Reductive elimination reactions are the reverse of oxidative addition reactions that
involve the coupling of two ligands and the elimination of its coupling product from the
metal center.59 One might think that an oxidative addition to a Zr(IV) metal center in its
complexes is impossible, considering Zr in the +4 oxidation state has a d0 electron

configuration. However, the Heyduk group was able to show that oxidative addition-like
and reductive elimination-like reactions can occur with Zr(IV), d0 complexes through the

cooperative redox reactivity of the redox-active ligand ap2- and the Zr(IV), d0 metal.
Figures 13a and 13b depict a Zr(IV), d0 complex undergoing an oxidative addition-like

reaction with Cl2 or PhICl2 in which the ap2- ligands are oxidized to iminosemiquinone
(isq-) and another Zr(IV), d0 complex undergoing a reductive elimination-like reaction
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involving the generation of a biaryl product in which the isq- ligands are reduced back to
ap2-. During the course of these reactions, the oxidation state of Zr remains +4 while the

ligands act as electron sources or sinks. Importantly, the Heyduk group was able to
demonstrate new mechanistic pathways for transition metal complexes containing a Group
4 transition metal that could mediate reactions involving bond formation.57,58

Figure 13a: Ligand-based oxidative addition-like reaction of a Zr(IV), d0 complex.

Figure 13b: Ligand-based reductive elimination-like reaction of a Zr(IV), d0 complex.
2.5 Redox Activity Potential of Azodioxides
Since cis-Ph(O)NN(O)Ph shows considerable n delocalization, it has the potential

to behave as a redox-active ligand. As shown in Figure 14, a neutral azodioxide ligand (1)

could potentially be subjected to a one-electron reduction to form a radical monoanion (2),

followed by another one-electron reduction to a closed-shell dianion (3). On the other hand,
the neutral azodioxide (1) could also potentially be subjected to a one-electron oxidation

to form a radical monocation (4), followed by another one-electron oxidation to a closedshell dication (5). A metal center M in an azodioxide complex with an oxidation state n
22

(when considering the azodioxide ligand as 1) could more accurately be represented as
having an oxidation state of n + 1, n + 2, n - 1, or n - 2, if the azodioxide ligand is acting
as 2, 3, 4, or 5, respectively.
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Figure 14: Possible redox states of azodioxides in their free and coordinated forms.
However, prior to our work, redox activity studies had not been conducted on

azodioxide metal complexes. When the Nicholas group studied the complex salt

[Fe{Ph(O)NN(O)Ph}3](FeCl4)2, the presence of FeCl4- anions become problematic when
it comes to measuring the electronic properties and redox activity of the compound.60 This

is because FeCl4- is a highly paramagnetic anion, with five unpaired electrons. As a result,

the presence of this anion would make magnetic and spectroscopic measurements of the
complex salt difficult to interpret. Specifically, since FeCl4- has five unpaired electrons, it

has a large magnetic susceptibility, meaning it could overshadow the magnetic
susceptibility signal resulting from the unpaired electrons in the complex cation
[Fe{Ph(O)NN(O)Ph}3]2+. Also, regarding spectroscopic analysis, FeCl4- would show
absorption peaks in UV-visible spectroscopy, although the peaks would not be too intense
since the anion’s transitions are spin-forbidden, in which the molar extinction coefficients

(s) for the absorption at each wavelength would be quite small.51 For example, a visible
spectrum of the salt NH4FeCl4 in diethyl ether has three maximum absorption peaks at 534,

619, and 688 nm with molar extinction coefficients of 1.4, 0.52, and 0.72 M-1-cm-1,
23

respectively. These weak absorption bands are known to be characteristic for the FeCl4-

anion.61 Furthermore, a UV spectrum of the salt NaFeCl4 in the gaseous state has three
maximum absorption bands at 240, 310, and 360 nm with molar extinction coefficients of

4.2 x 10-3, 2.7 x 10-3, and 2.5 x 10-3 M-^cm-1, respectively. These weak absorption peaks
are also known to be characteristic for the FeCl4- anion.62 Thus, for redox activity studies

on azodioxide complexes to be performed, complex salts containing cationic azodioxide
complexes with diamagnetic, redox-stable, and noncoordinating (or at least weakly
coordinating) anions had to be synthesized.
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CHAPTER III

SYNTHESIS AND CHARACTERIZATION OF A MIXED-LIGAND COBALT(II)

BIPYRIDYL/DIPHENYLAZODIOXIDE COMPLEX SALT

3.1 Rationale
Since a former graduate student in my research group (Dr. Lakshmi Balaraman)

studied 1st-row transition metal azodioxide complexes that are homoleptic (and, as I have
previously mentioned, I had the privilege of working on some of this chemistry as an

undergraduate), the first goal of this project was to synthesize and characterize a 1st-row
transition metal azodioxide complex that is heteroleptic (a complex with at least two

different types of ligands). In particular, our interest was to synthesize at least one complex
that contains both azodioxide and another ligand with known redox activity, since
complexes like these had not been reported in the literature prior to our work. The specific

heteroleptic complexes of interest are those with azodioxide and bpy ligands. (See Chapter
II, Section 2.2 for the details on the redox activity of bpy.)

For the synthesis of bpy/azodioxide complexes, it was desired to prepare their
cationic heteroleptic complexes with counteranions that are diamagnetic, redox-stable, and

non-coordinating or weakly coordinating (to prevent strong interactions between the cation
and anion), if we wished to conduct redox activity studies. An example of such a
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counteranion is hexafluorophosphate (PF6-). Since this counteranion’s structure is
symmetrical, it is able to distribute the -1 charge equally among the six F atoms, making

PF6- weakly coordinating. Also, the highly electronegative F atoms in PF6- decrease the
overall Lewis basicity of PF6-. Unfortunately, it was noted by Nicholas’ group that attempts

to prepare salts of his cation [Fe{Ph(O)NN(O)Ph}3]2+ with BF4- or BPh4- as counteranions

were unsuccessful.63 Furthermore, we hypothesized that the presence of chloride (Cl-) in
the reaction mixture in Nicholas’ group’s preparation of [Fe{Ph(O)NN(O)Ph}3](FeCl4)2

led to the oxidation of some Fe(II) to Fe(III). Since Cl- is a n-donor ligand (a ligand
containing at least one additional lone pair of electrons in a donor atom’s p orbitals that is

able to donate the electrons to a metal’s empty n-symmetry d orbitals64) that can stabilize
metals in higher oxidation states, soluble Cl- could favor the formation of the problematic
FeCl4- anion. When broadening this type of synthesis to other transition metals, production

of similar MClxy- anions could remain an issue. Therefore, a synthetic strategy removing
soluble Cl- from the reaction mixture before PhNO is added was implemented.

Since my former lab-mate, Dr. Lakshmi Balaraman, had success in preparing a
homoleptic cobalt(II) azodioxide complex cation with PF6- counteranions, I decided to
attempt the synthesis of a cationic, heteroleptic bpy/azodioxide complex with cobalt as the

metal center and PF6- counteranions.

3.2 Synthetic Strategy
The cobalt(II) species Co(bpy)Cl2 was used as a synthon in the synthesis of a cobalt

bpy/azodioxide complex. This synthon was prepared following a procedure reported by

Iqbal and coworkers,65 albeit with minor modifications.66 The synthesis of Co(bpy)Cl2 is
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depicted in Figure 15. The details of this preparation are explained in Section 3.4.2 of this
chapter.

Figure 15: Synthesis of Co(bpy)Cl2.
The first step in the synthesis of a cobalt bpy/azodioxide complex involved treating

a suspension of Co(bpy)Cl2 in acetonitrile (MeCN) with a solution of 2 equivalents of
TlPF6 (thallium hexafluorophosphate) in MeCN to remove Cl- as insoluble TlCl and form

a solution of a proposed reaction intermediate of the form [Co(bpy)(NCMe)n]2+, where n
is likely equal to 2 or 4.66 Although thallium compounds are toxic, TlPF6 was used to
remove Cl- as TlCl, rather than the safer AgPF6 (silver hexafluorophosphate) being used to

precipitate AgCl, because Tl+, unlike Ag+, is not a strong oxidizing agent, and we wished

to avoid any possible oxidation of Co(II) to Co(III). Also, it is worth mentioning that MeCN
is known for being a good coordinating solvent. A good coordinating solvent like MeCN

was necessary for our specific synthesis in order to allow for Cl- removal by TlCl

precipitation. Generally, it is more favorable to remove Cl- from the reaction mixture if it
will lead to the formation of a solvated complex ion such as [Co(bpy)(NCMe)n]2+, where
n = 2 or 4, as opposed to poorly solvated ions in a more weakly coordinating solvent.67
After stirring the reaction mixture long enough to ensure that the precipitation of TlCl was
complete in the first step of the synthesis, 6 equivalents (an excess) of PhNO

(nitrosobenzene) in MeCN were added to the reaction mixture containing the proposed
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[Co(bpy)(NCMe)n]2+ intermediate. This reaction resulted in the formation of a cobalt
bpy/azodioxide complex salt of the form [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2. The

synthesis of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 is depicted in Figure 16 and has been
published in ACS Omega.66 Once the reaction was complete, TlCl was removed by
filtration from the reaction mixture, followed by the removal of MeCN solvent from the
filtrate in vacuo. Recrystallization from a mixture of dichloromethane (DCM) and diethyl

ether (Et2O) yielded garnet-red crystals of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2.66

Figure 16: Synthesis of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2.
3.3 Characterization of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2
3.3.1 Single-Crystal X-Ray Diffraction

Single-crystal X-ray diffraction, generally the “gold standard” of characterization

techniques in inorganic chemistry, was performed by Prof. Wiley Youngs’ former Ph.D.
student Dr. Michael Stromyer at the University of Akron in order to determine the structure

of our cobalt bpy/azodioxide complex salt reaction product. This characterization allowed

for the determination not only of the product’s topology, but also its bond lengths and bond

angles. Its crystal structure as a thermal ellipsoid plot66 is presented in Figure 17.
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Figure 17: Thermal ellipsoid plot of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2. The
recrystallization solvent CH2Cl2 is present in the crystal lattice.
It

is

important

to

note

that

the

six-coordinate

complex

cation

[Co(bpy){Ph(O)NN(O)Ph}2]2+ has a trigonal prismatic coordination geometry. Most six-

coordinate transition metal complexes display octahedral, rather than trigonal prismatic

geometry. A trigonal prismatic geometry is usually less common than an octahedral
geometry for two reasons: each ligand in a transition metal complex with a trigonal

prismatic geometry is in an eclipsed conformation in relation to another ligand, resulting
in more ligand-ligand repulsion68 than that in an octahedral geometry, and trigonal

prismatic complexes, in many cases, have smaller ligand field stabilization energies68 (this

energy is the difference between the d-electron energy of a complex and that of a free
atom/ion69) than those of octahedral complexes, meaning trigonal prismatic complexes are
usually more reactive or less stable than the comparable octahedral complexes. Therefore,

the formation of trigonal prismatic complexes usually requires ligand-ligand interactions
that are favorable. An important example of a class of ligands in which the ligand-ligand
interactions are favorable is the dithiolenes (R2C2S2), which are bidentate chelating ligands

that contain S donor atoms.70 More specifically, dithiolene ligands in transition metal
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complexes have been proposed to experience inter-ligand S-S interactions. These S-S

interactions, which are considered direct and weak, are proposed to make the trigonal

prismatic geometry that exists in dithiolene complexes stable.71,72 Other trigonal prismatic
complexes require the implementation of small o-donating ligands (e.g. CHs’) and d metal
ions so that n-bonding effects are not present and steric effects are minimized.70 An

example of such a complex is the highly reactive organometallic

species

hexamethyltungsten(VI), W(CH3)6.73

Furthermore, trigonal prismatic Co(II) complexes are particularly unusual, as most
Co(II) complexes are either tetrahedral or octahedral.74 Most crystallographically

characterized Co(II) complexes with trigonal prismatic geometry possess rigid,
complicated

hexadentate

ligands

that

are

known

as

clathrochelates75

or

pseudoclathrochelates.68,76 These types of ligands possess six coordinating atoms each that

are arranged to encapsulate metal ions, resulting in the formation of trigonal prismatic

“cage” complexes where the geometry of the ligand’s donor atoms enforces the trigonal
prismatic coordination geometry.68,75,76 Another example of a structurally characterized
Co(II) trigonal prismatic complex that contains a hexadentate ligand is [Co(hpy)]Br2, where
hpy = tris([2,2'-bipyridin]-6-yl)methanol, but unlike the other clathrochelate and
pseudoclathrochelate examples that have been cited, this complex contains a redox-active
ligand with a n system that is extended.77 Prior to our work, however, only two
monometallic, trigonal prismatic Co(II) complexes containing only bidentate ligands had

been crystallographically characterized: Co(NO2phen)(3,6-DBSQ)2 (NO2phen = 5-nitro1,10-phenanthroline and 3,6-DBSQ- = 3,6-di-tert-butylsemiquinone) and Co(dafl)(3,6DBSQ)2 (dafl = 4,5-diaza-fluoren-9-one).78
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More

importantly,

not

only

does

our

complex

cation

[Co(bpy){Ph(O)NN(O)Ph}2]2+ possess a trigonal prismatic coordination geometry, but the
complex cation [Fe{Ph(O)NN(O)Ph}3]2+, from Nicholas’ group, also possesses this

geometry. (Refer back to Figures 8a and 8b in Chapter I, Section 1.6.1) A plausible
hypothesis for why a trigonal prismatic geometry is observed in both complex cations is
that the azodioxide ligand cis-Ph(O)NN(O)Ph is isolobal with dithiolene dianions

(R2C2S22-). The term “isolobal,” devised by the great theoretical chemist Roald Hoffmann,

is used to describe molecules, ions, or fragments of molecules which have similar energy,

symmetry, and electron occupation of their frontier orbitals. In other words, isolobal
fragments suggest the possibility of similarities in bonding between fragments that might

otherwise seem unrelated. As an example, two fragments that are considered isolobal are

CH3 (the methyl radical) and Mn(CO)5 (an organometallic fragment with a d7 electron
count) since each has one electron occupying its highest energy hybrid frontier orbital, and

each must form one bond to achieve a closed shell on its central atom (an octet of electrons
on C and 18 electrons on Mn).79 Transition metal dithiolene complexes, which have the
form M(R2C2S2)3 (in which “M” is an early transition metal and in which the complex can

be neutral, cationic, or anionic) often possess a trigonal prismatic coordination
geometry.72,80 Moreover, dithiolene has different redox states and may be considered as

R2C2S22- (a closed-shell dianion), R2C2S2- (a radical monoanion), or R2C2S2 (a neutral,
closed-shell species). Similarly, as it was previously mentioned in Chapter II, Section 2.5,
the neutral azodioxide ligand Ph(O)NN(O)Ph may be considered as [Ph(O)NN(O)Ph]+ (a

radical monocation) or [Ph(O)NN(O)Ph]2+ (a closed-shell dication).66 Importantly, as it

was mentioned earlier, inter-ligand S-S interactions are favorable in dithiolenes,70 so in
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this aspect, the observation of a trigonal prismatic coordination geometry in the transition

metal tris(dithiolene) complexes, M(R2C2S2)3, is not surprising. Additionally, chelating

ligands with a small bite angle (ligand-metal-ligand angle) formed can result in a distortion
from an octahedral geometry to a trigonal prismatic geometry.70
As shown in Table I, the average N-N and N-O bond lengths in

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2

similar

are

to

those

in

uncoordinated

cis-

Ph(O)NN(O)Ph and in the azodioxide complexes63,66 [Fe{Ph(O)NN(O)Ph}3](FeCl4)2 and

[Co{Ph(O)NN(O)Ph}4](PF6)2, as well as in the non-d0 azodioxide complexes81,82

Sc(OTf)3(H2O)2{Ar(O)NN(O)Ar} and

[Ca{Ph(O)NN(O)Ph}(H2O)2(THF)3]I2.66 The

near-invariance of these bond lengths suggests the azodioxide ligand Ph(O)NN(O)Ph may
not be either a strong n-acceptor or a strong n-donor ligand, so coordination to a metal does
not significantly deplete the population of a n-bonding MO or increase the population of a

n-antibonding

one.

In

contrast,

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2

the

average

much

are

Co-O

shorter

bond

lengths

in

than

those

in

[Co{Ph(O)NN(O)Ph}4](PF6)2 and the average Sc-O and Ca-O bond lengths81,82 in

Sc(OTf)3(H2O)2{Ar(O)NN(O)Ar}
respectively.66

Interestingly,

and

the

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 are

[Ca{Ph(O)NN(O)Ph}(H2O)2(THF)3]I2,

average
similar to

Co-O

the

bond

Fe-O

bond

lengths
lengths

in

in

[Fe{Ph(O)NN(O)Ph}3](FeCl4)2. This result is intriguing in light of the fact that the Co
metal center in [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 has an oxidation state of +2 with a d7

electron count, whereas the Fe in [Fe{Ph(O)NN(O)Ph}3](FeCl4)2 has an oxidation state of

+2 with a d6 electron count. Therefore, the X-ray crystallography data suggest that M-O
(M = Fe, Co) bond lengths in azodioxide complexes might show a stronger dependence on
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coordination number, which is perhaps due to steric effects from the ligands, than on the
d-electron

count

and

identity

of

the

metal.66

However,

the

[Ca{Ph(O)NN(O)Ph}(H2O)2(THF)3]I2 complex has a coordination number of 7, as does
the Sc(III) azodioxide complex,81,82 but it has average Ca-O bond lengths greater than the

average Co-O bond lengths in [Co{Ph(O)NN(O)Ph}4](PF6)2, which has a coordination
number of 8. In fact, the Ca(II) azodioxide complex has the longest M-O bond length out
of all five of the structurally characterized azodioxide complexes. It is possible that there
is a strong ion-dipole interaction between cis-Ph(O)NN(O)Ph and Ca, an alkaline earth

metal, that contributes to the nature of their bonding, which causes the Ca-O bond lengths
in the Ca(II) azodioxide complex to be longer than M-O bond lengths in the other four
azodioxide complexes since the M-O bonds in the other complexes have greater covalent

bonding character because in these cases, cis-Ph(O)NN(O)Ph is able to bond to transition
metals containing valence d orbitals. Nevertheless, in order to determine if the strong

dependency of M-O bond lengths on metal coordination number is a general trend, more
azodioxide metal complexes must be synthesized and crystallographically characterized.

Additionally, it is important to point out that [Co{Ph(O)NN(O)Ph}4](PF6)2 is the only

known azodioxide complex in which the chelate rings are in a “puckered” (envelope)
conformation, causing the Co metal center to lie outside the plane. The other azodioxide

complexes, on the other hand, have planar chelate rings.66
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Compound

Average Average Average
M-O
N-N
N-O
bond
bond
bond
length
length
length
(A)
(A)
(A)

Chelate
rings

cis-Ph(O)NN(O)Ph

1.32

1.27

—

—

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2

1.31

1.28

2.10

planar

[Fe{Ph(O)NN(O)Ph}3](FeCl4)2

1.29

1.28

2.12

planar

[Co{Ph(O)NN(O)Ph}4](PF6)2

1.31

1.28

2.24

puckered

Sc(OTf)3(H2O)2{Ar(O)NN(O)Ar}

1.29

1.28

2.21

planar

[Ca{Ph(O)NN(O)Ph}(H2O)2(THF)3]l2

1.30

1.27

2.42

planar

*OTf = OSO2CF3, Ar = 2-MeOC6H4

Table I: Important structural parameters for cis-Ph(O)NN(O)Ph and its corresponding Fe
and Co complexes.66
With a crystal structure obtained for [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2, it is

especially important to note that this complex salt is the first structurally characterized

heteroleptic complex containing azodioxide and a known redox-active ligand.66 By
publishing the synthesis and characterization of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2, we

were able to add more azodioxide metal complexes to the very few reported in the literature
and further develop the coordination chemistry of azodioxides. However, since a single

crystal (one that was used for single-crystal X-ray diffraction) may not constitute the bulk
of a material or product,83 other characterization techniques were applied in order to

establish the identity of our new complex salt.
3.3.2 Elemental Analysis (CHN Analysis)

After obtaining a crystal structure of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2, elemental

analysis was performed on our compound by Galbraith Laboratories, Inc (Knoxville, TN)
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in order to determine the compound’s purity. More specifically, the carbon, hydrogen, and
nitrogen (CHN) content of our compound was determined via sample combustion.

The

experimentally

determined

percentages

of

C,

H,

and

N

for

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 were 38.81%, 2.65%, and 10.29%, respectively. The
theoretical (expected) percentages of C, H, and N for our compound are 43.75%, 3.02%,
and 9.00%, respectively.66 It is important to note that the carbon content of our compound

is ~5% lower than expected, whereas its nitrogen content is ~1.3% higher than expected.

The experimentally determined lower percentage of carbon is likely due to the presence of

thallium-containing impurities since we used TlPF6 as part of our synthetic scheme for
[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2. Importantly, the high molar mass of thallium (204.37

g/mol) could have possibly caused the determination of a lower percentage of carbon in
our compound, as a small per-mole impurity of a thallium compound corresponds to a

larger mass percent impurity. Moreover, the specific impurity containing lower carbon
content that is likely present in our bulk [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 product is the
reaction intermediate [Co(bpy)(NCMe)n]2+, where n = 2 or 4.66 The presence of this
reaction intermediate is probable because MeCN coordinates strongly to the metal center,

which makes it difficult to displace by the azodioxide ligand in the second step of our

synthetic scheme for

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2. Meanwhile, the higher

percentage of nitrogen that was experimentally determined for our compound is likely due

to a small PhNO impurity, which is probable because excess PhNO was used in the

synthesis of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2.66

3.3.3 UV-Visible Spectroscopy
UV-visible spectroscopy was performed on [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2
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in order to determine the types of electronic transitions it experiences, so that we could
gain information about its electronic structure. When taking UV-visible absorption spectra

of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 in MeCN, the spectra had revealed two peaks with

maximum absorbances at wavelengths (Xmax) of 246 nm and 304 nm.66 (See Figure 18a.)
With this information, we were able to calculate molar absorptivity (a) values for each Xmax
using the Beer-Lambert law of A = aLc, where A = absorbance, L = path length of cuvette,

c = concentration of analyte. The molar absorptivity represents the absorption strength of

a compound at a particular wavelength.84 For our Beer-Lambert law study, we were able
to observe the expected linear relationship between absorbance and concentration when we

worked with low concentrations of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 in the 10-5 M range.
The experimental molar absorptivities at 246 nm and 304 nm were 1.38 x 104 M'■cm'1

and 2.26 x 104 M’1-cm’1, respectively. The absorption at 246 nm is likely due to a

ligand-centered n ^ n* transition at the bpy ligand in [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2.66

The n ^ n* transition is usually intense, with a values ranging from 5,000-100,000 M'^cm'

1.85 These transitions are commonly observed in the UV region (200-400 nm) of a UV-

visible spectrum. Moreover, this type of electronic transition involves orbitals with high
overlap, making the probability of the transition large.86 This assignment of a n ^ n*
transition at 246 nm is based on the fact that a UV-visible spectrum of uncoordinated bpy

in MeCN showed a maximum absorbance peak at Xmax = 237 nm (a = 2.78 x 104 M<cm-

1). An experimental UV-visible spectrum of bpy is shown in Figure 18b. On the other hand,
the absorption at 304 nm is likely due to a charge transfer (e.g. metal-to-ligand (MLCT),

ligand-to-metal (LMCT) between cis-Ph(O)NN(O)Ph and Co, since the UV-visible spectra
of [Co{Ph(O)NN(O)Ph}4](PF6)2 show a maximum absorption peak at almost the same
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wavelength, Xmax = 305 nm (s = 4.62 x 104 M-^cm-1).66 An experimental UV-visible

spectrum of the homoleptic Co(II) azodioxide complex [Co{Ph(O)NN(O)Ph}4](PF6)2 is

depicted in Figure 18c. Charge transfer transitions are typically strong, with s values

ranging from 1,000 to 50,000 M-1-cm-1. These transitions are also fully “allowed” by the
spectroscopic selection rules.87
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Figure 18: Experimental UV-visible spectra of solutions of (a)
[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 in MeCN (b) bpy in MeCN (c)
[Co{Ph(O)NN(O)Ph}4](PF6)2 in MeCN.
3.3.4 IR Spectroscopy

Solid-phase infrared (IR) spectroscopy in attenuated total reflectance (ATR) mode

was conducted on [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 in order to confirm the presence of

particular functional groups. The ATR mode was chosen for IR analysis because when our

38

air-sensitive compound is in the solid phase, as opposed to the solution phase, O2 cannot

readily diffuse into it.

The experimental IR spectrum of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2, shown in
Figure 19a, appears to have three broad peaks in the N-O stretching region: 1370 cm-1,

1444

cm-1,

and

1478

cm-1.66,88

In

fact,

the

IR

spectra

of

homoleptic

[Co{Ph(O)NN(O)Ph}4](PF6)2 and uncoordinated cis-Ph(O)NN(O)Ph also each display
three intense N-O stretches from 1370-1390 cm-1 and 1458-1485 cm-1. The experimental

IR spectrum of cis-Ph(O)NN(O)Ph that was taken in ATR mode is shown in Figure 19b.
The weak IR peak at 1577 cm-1 in Figure 19a is possibly a C=N stretch, due to its presence
in the bpy ligand.66 Although the C=N stretching region ranges from 1640 - 1690 cm-1,89

it is possible that the observed frequency is lower because the C-N bonds in bpy have a
bond order between 1 and 2 due to n delocalization in the aromatic rings. The experimental

IR spectrum of bpy that was taken in ATR mode is shown in Figure 19c. Lastly, two
important IR stretches to note in the IR spectrum of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2

(Figure 19a) are the broad stretches at 3534 cm-1 and 3606 cm-1. These peaks are located at
unusually high energies within the N-H and O-H functional group region. However,

neither N-H nor O-H moieties are present in [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2. It is
possible that these peaks arise from charge transfer (e.g. MLCT, LMCT) between cis-

Ph(O)NN(O)Ph and Co.66
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Figure 19: Experimental solid-phase IR spectra of (a) [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2
(b) cis-Ph(O)NN(O)Ph (c) bpy.
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3.3.5 Magnetic Susceptibility

The magnetic susceptibility (x) of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 was
measured in order to determine its number of unpaired electrons and confirm the oxidation

state of cobalt so that we could gain further information on the complex’s electronic state.

Magnetic susceptibility measures a substance’s ability to be either attracted to or repelled
by a magnetic field.90 Using the measured magnetic susceptibility (x) and Bain and
Berry’s90 Pascal constants to correct for diamagnetism (which results due to the presence

of paired core electrons and paired electrons in covalent bonds), we were able to calculate

a solid-state effective magnetic moment (peg) of 4.74 Bohr magnetons (ub, where 1 pb =
9.274 x 10-24 J/T) at 22°C for our complex.66 The peff value is the measure of a complex’s
paramagnetism, with greater peff values corresponding to a more paramagnetic species.91

The experimentally determined magnetic moment of 4.74 pB is within the range of

magnetic moments (4.1-5.2 pB) seen for high-spin Co(II) complexes, which possess three
unpaired electrons.92 Often, when a 1st-row transition metal atom or ion is part of a

complex, its d electrons interact with their nonspherical environment, often causing the
orbital angular momentum to be quenched. This would mean that for some 1st-row
transition metal complexes with unpaired electrons, a spin-only magnetic moment could

be calculated since only the spin angular momentum would remain.91 However, high-spin
Co(II) complexes, which have a d7 electron configuration, have experimental magnetic

moments that deviate significantly from their theoretical spin-only magnetic moment,
which is only 3.87 pB. For example, the trigonal prismatic high-spin Co(II) complex salt

[Co(PccBF)](BF4), where PccBF- is the hexadentate clathrochelate fluoroborotris(2carboxaldoximo-6-pyridyl)phosphine, has a magnetic moment of 4.91 pB.93 This large
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deviation from spin-only magnetic moments is because high-spin 3d7 complexes have a
substantial orbital angular momentum contribution to their measured magnetic moments.

This orbital angular momentum is present in these complexes because they have at least
one unfilled (or half-filled) orbital with an energy that is similar to the orbitals that are

filled by unpaired electrons and are of the appropriate symmetry. When a magnetic field is
applied, this leads to the circulation of electrons around the metal with the use of these low-

lying orbitals, therefore resulting in the orbital angular momentum contribution to magnetic
moment.91 Thus, our calculated peg value of 4.74 pb for [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2

corresponds to a Co(II) metal center with three unpaired electrons, with a significant orbital
angular momentum contribution to the magnetic moment.66
3.3.6 EPR Spectroscopy

Electron paramagnetic resonance (EPR) spectroscopy is a characterization

technique that can be applied to paramagnetic transition metal complexes, that is,
complexes with at least one unpaired electron. In contrast to NMR spectroscopy, which

involves the interaction of electromagnetic radiation (EMR) with nuclei possessing
nonzero spin, EPR involves the interaction of EMR with the unpaired electrons in a

transition metal complex or even in an organic radical. Moreover, in EPR, the EMR

frequency is typically in the microwave region and is usually kept constant while the

magnetic field strength is varied. In NMR, the magnetic field strength is kept constant
while the frequency is varied.94 It is important to mention that before we conducted EPR

studies,

we

attempted

to

acquire

1H NMR

spectra

of our

paramagnetic

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2. However, our NMR spectra did not show any peaks
of this compound; instead, small amounts of the impurity PhNO were detected, which was
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confirmed by spiking experiments.66
EPR spectroscopic measurements were conducted on our complex salt

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 in order to gain further information about its electronic

state, in addition to what we had determined using UV-visible spectroscopy and magnetic

susceptibility. Transition metal complexes with more than one unpaired electron can have
very fast relaxation times at room temperature, which makes their EPR signals too broad

to detect.95 In fact, we first attempted to acquire a room-temperature EPR spectrum of our
complex from the instrument in Dr. Sudha Chakrapani’s group at the Case Western

Reserve University School of Medicine, but the EPR signal was broad enough to be barely
visible over the baseline noise. Therefore, low-temperature EPR studies at 4.5 K were

conducted on our complex, in which liquid helium was used to cool it so that the relaxation

would not be as efficient.
The low-temperature EPR spectrum of our complex was taken at Miami University,
in collaboration with Dr. Robert McCarrick and Prof. David Tierney. The EPR spectrum
of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 as a plot of the first derivative of signal intensity
d(signal)/dB vs. magnetic field strength (B) in units of Gauss (G) is presented in Figure 20.

Importantly, this EPR spectrum shows that d(signal)/dB = 0 at around a magnetic field

strength of 1670 G, which converted to Tesla (T) would be 0.167 T. Using this value of

0.167 T, we were able to calculate the g-factor,95 which is a numerical value that is a
distinguishing feature of molecules with unpaired electrons. The g-factor for

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 was calculated using the formula hv = gpbB . Here, hv
is the energy of a photon (of EMR) with the frequency (v) being equal to the microwave

frequency used for our EPR studies (9.629 GHz), p b is a constant equal to 9.274 x 10-24
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J/T, and B for this signal is 0.167 T. Our calculated g-factor was approximately equal to

4.12. This g-factor of 4.12 indicates that the unpaired electrons (radical character) are

primarily centered on the Co metal ion in [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2. If the
unpaired electrons were mainly centered on main-group atoms such as O or N atoms in our

complex, then the g-factor would be extremely close to that of a free electron (for which g
= 2.0023), in the range of 1.99-2.01.95 Furthermore, many transition metal ions as part of

complexes, especially those with more than one unpaired electron, have g-factors that are

significantly different from 2.0023 because their orbital angular momentum is partially or
completely quenched.96 Additionally, the two most common oxidation states for cobalt are

+2 and +3, with most Co(II) complexes being high-spin (three unpaired electrons) and most
Co(III) complexes being low-spin (no unpaired electrons, hence no EPR signal).74
Therefore, our EPR results offer further confirmation that the Co center in

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 is in the +2 oxidation state with three unpaired
electrons (high-spin). Another important feature to note in the EPR spectrum of

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 (Figure 18) is the splitting around the 1670 G signal.
This splitting is likely caused by a hyperfine coupling95 in which the unpaired electrons are
interacting with its 59Co nucleus (the isotope with 100% natural abundance), which has a

spin of 7/2, making it magnetic. Finally, there can be seen in the acquired EPR spectrum a
small signal around B = 11900 G. This signal very likely corresponds to a small O2

impurity, since the EPR sample was prepared in a glove bag at Miami University, which
does not have as anaerobic of an environment as our glovebox, and O2 is itself a triplet

diradical in its ground state.97
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Figure 20: EPR spectrum of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2.
3.4 Experimental Methods
3.4.1 General Experimental Considerations

Elemental Analysis was carried out at Galbraith Laboratories, Inc in Knoxville, TN.

A Shimadzu UV-2600 spectrometer was used to acquire UV-visible spectra of solutions of

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 in MeCN in gastight cuvettes, which have a 1.2 cm
path length. A PerkinElmer Spectrum 2 spectrometer was used to acquire IR spectra of

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 as a neat solid in ATR mode. A Sherwood Scientific
MK 1 magnetic susceptibility balance was used to obtain the magnetic susceptibility

measurement. A Bruker Avance III 400 MHz spectrometer was used to obtain NMR
spectra.66 The EPR spectrum of a solution of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 in MeCN

and DCM, that was prepared in a glovebag, was obtained at 4.5 K at Miami University
using a Bruker X-band EPR spectrometer with a microwave frequency of 9.629 GHz.

Solvents used for synthesis and characterization were sparged with nitrogen to remove O2
and dried through an activated alumina column in an MBraun MB-SPS solvent purification

system.

Reagents

that

were

used

in
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the

syntheses

of

Co(bpy)Cl2

and

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 were purchased from Sigma-Aldrich, Fisher, Strem,
and TCI.66
3.4.2 Single-Crystal X-Ray Diffraction Experiment

A garnet-red crystal of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 was coated in paratone
oil and then mounted on a CryoLoop. This CryoLoop was then placed on a goniometer
under a nitrogen stream. The data set for the crystal structure was obtained on a Bruker
Kappa APEX II Duo CCD system that was supplied with an Mo ImuS source and a Cu

ImuS micro-focus source provided with QUAZAR optics (1 = 1.54178 A). Using

reflections from three different orientations, the unit cell of the crystal structure was
determined. APEX II software packages were used to collect the data set, the APEX II
software suite was used to process the data set, and SAINT was used to integrate the data

set. Using multi-scan SADABS, an empirical absorption correction as well as other
corrections were applied to the data set. Using the Bruker SHELXTL package, structure

solution, refinement, and modelling were performed. The crystal structure of

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 was determined by the full-matrix least-squares
refinement of F2 and the selection of appropriate atoms from the difference map. Hydrogen
atoms were calculated and Uiso(H) values were fixed based on a riding model.66

Crystal

data

for

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2(CH2Cl2):

C35H30CI2COF12N6O4P2, M = 1018.42 g/mol, monoclinic unit cell, a = 28.0797(9) A, b =

13.4393(4) A, c = 25.3112(8) A, a = 90°, p = 103.746(2)°, y = 90°, V = 9278.2(5) A3, T =
100(2) K, space group C2/c, Z = 8,57343 reflections measured, 9419 independent

reflections (Rint = 0.0725). The final R1 values were 0.0775 (I > 2o(I)). The final wR(F2)
values were 0.2463 (I > 2o(I)). The final R1 values were 0.1171 (all data). The final wR (F2)
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values were 0.2832 (all data). Using PLATON SQUEEZE, two disordered CH2Cl2

molecules were removed.66

3.4.3 Synthesis of Co(bpy)Cl2
The synthesis of the Co(II) synthon Co(bpy)Cl2 was followed from a procedure
reported by Iqbal and coworkers,65 albeit with minor modifications. A solution of 1.57 g

(9.92 mmol) bpy in 30 mL MeCN was treated with 1.28 g (9.86 mmol) solid anhydrous
CoCl2. This reaction was carried out in an MBraun air- and moisture-free nitrogen
glovebox for 24 hours at room temperature and resulted in the formation of a light blue

precipitate. Once the reaction was complete, MeCN solvent was removed in vacuo and the
light blue powder was washed with Et2O and dried under vacuum in order to yield 0.74 g
(26%) of the light blue Co(bpy)Cl2.66
3.4.4 Synthesis of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2

0.517 g (1.79 mmol) of the light blue-colored Co(II) synthon Co(bpy)Cl2 was
suspended in 50 mL MeCN. A solution of 1.31 g (3.75 mmol) TlPF6 in 10 mL MeCN was
added to the Co(bpy)Cl2 suspension, which resulted in the formation of TlCl as a white

precipitate, along with a color change of the solution from blue to a peach color. After
waiting for 30 minutes, 1.15 g (10.7 mmol) PhNO in 25 mL MeCN was added to the

reaction mixture, turning the mixture a deep green. The reaction was carried out in an

MBraun air- and moisture-free nitrogen glovebox for 2.5 days at room temperature. Due

to the deep green color of PhNO, no further color changes were observed throughout the

reaction. Once the reaction was complete, the white solid TlCl was removed from the
reaction mixture by filtration through a medium glass-fritted funnel, followed by the

removal of MeCN solvent from the filtrate in vacuo in order to yield the crude
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[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 product. Recrystallization of the product was then
performed by the following two steps: first the crude product was dissolved in minimal

DCM and kept in the glovebox freezer (-30°C) for 24-48 hours so that any unreacted PhNO
dimer could precipitate; the vials were then filled about halfway with the supernatant, and

Et2O was layered atop the supernatant. The vials were then kept in the glovebox freezer for
72 hours to yield garnet-red crystals of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2. The overall

product yield was 0.25 g (0.27 mmol, 15%).66
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CHAPTER IV
REDOX ACTIVITY STUDIES OF THE COBALT(II)

BIPYRIDYL/DIPHENYLAZODIOXIDE COMPLEX SALT USING

ELECTROCHEMICAL METHODS

4.1 Rationale
Once the

synthesis

and

initial

characterization

of the

complex

salt

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 was completed, the next focus of this project was to
continue the characterization of this compound by investigating the potential redox activity
of its azodioxide ligands. As discussed in Chapter II, Section 2.5, we hypothesized that
azodioxides may be able to display redox activity, based on their significant n

delocalization. This hypothesis is supported by the fact that Ph(O)NN(O)Ph has N-O and

N-N bond lengths that correspond to substantial n delocalization, both as a free molecule98
and as a ligand99 in complexes. In addition, evidence of redox activity has been reported in

free nitrosoarenes, ArNO (the monomers of diarylazodioxides),100,101 as well as in
complexes in which ArNO is considered a neutral ligand,102 a radical monoanion

(ArNO^-),102,103 or a closed-shell dianion (ArNO2-).102,104 In this respect, ArNO species are
electronically somewhat similar to O2.100 However, prior to our work, the redox activity of
azodioxide complexes had not been studied. It is important to note that, since our newly
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prepared heteroleptic complex contains a non-azodioxide ligand, bpy, which has long been
known to be redox-active itself,105 we believed that it was quite likely that this novel
complex would display some ligand-based redox activity due to bpy, even if the azodioxide

ligands did not contribute to this property.
We

decided

to

investigate

the

redox

activity

of

the

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 complex salt using electrochemical techniques, in

particular,

cyclic

voltammetry

(CV)

and

UV-visible

spectroelectrochemistry.

Electrochemical techniques are very useful in the study of electron-transfer reactions, by

measuring the ability of an applied potential to induce oxidation or reduction (redox)
reactions in the compounds studied. CV, in which the applied electrode potential is varied

over time and the resulting current is measured, is particularly useful in the characterization
of redox processes of molecular species. In fact, CV has become a widely used

electrochemical method for conducting initial electrochemical studies of new systems106

(in our case, azodioxide complexes). Moreover, the related method of UV-visible
spectroelectrochemistry has the capability of identifying redox processes along with the

corresponding species (such as reactive intermediates or products) at each step in a redox
reaction.107 UV-visible spectroelectrochemistry can thus be utilized to further understand
redox processes that were initially examined by CV. Importantly, the use of both CV and

UV-visible spectroelectrochemical methods can help indicate whether the redox activity in

novel transition metal complexes is primarily metal-based or ligand-based.
4.2 Background on Electrochemical Studies for Nitrosoarenes and its Complexes
As redox activity studies of ArNO and their complexes have been reported, we were

interested in obtaining from the literature background information on investigations of the
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redox activity of ArNO that employed electrochemical methods, since this information was

potentially

useful

as

a

comparison

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2,

which

to

our

contains

electrochemical
the

studies

ArNO-related

of

ligand

diphenylazodioxide, Ph(O)NN(O)Ph. In particular, some research groups have reported

extensive electrochemical data on free ArNO molecules as well as on ArNO complexes.

Lessard and coworkers performed CV studies in the potential window of -1.00 to -

2.60 V vs. Ag/AgNO3 (0.05 M) of PhNO, azoxybenzene (Ph(O)NNPh), and azobenzene

(PhNNPh) in organic solvents. The CV studies of PhNO showed one reversible redox

couple, PhNO/[PhNOy-, with a cathodic peak at -1.39 V vs. Ag/AgNOs (0.05 M) and an

anodic peak at -1.32 V; an irreversible cathodic peak at -2.29 V corresponding to the oneelectron reduction of [PhNOy- to [PhNO]2-; and a second reversible redox couple,

Ph(O)NNPh/[Ph(O)NNPhy-, with a cathodic peak at -1.84 V and an anodic peak at -1.77
V. The Ph(O)NNPh species is proposed to be formed in situ from a reaction of [PhNO]’-

with residual water that also involves the elimination of OH-. The CV studies for
Ph(O)NNPh showed one reversible redox couple, Ph(O)NNPh/[Ph(O)NNPh] ’’, with a

cathodic peak at -1.84 V vs. Ag/AgNO3 and an anodic peak at -1.75 V, which is in

agreement with the reversible redox couple Ph(O)NNPh/[Ph(O)NNPhy- at -1.84 V/-1.77
V in the CV studies of PhNO; an irreversible cathodic peak at -2.24 V that corresponded
to [Ph(O)NNPhy- being reduced to [PhNNPhy-, the azobenzene radical monoanion, which
forms as a result of a multistep reaction process involving disproportionation, protonation,
and two-electron-transfer steps; and a second irreversible cathodic peak at -2.35 V that

corresponded to the one-electron reduction of [PhNNPhy- to [PhNNPh]2-. The CV studies
for PhNNPh showed one reversible redox couple, PhNNPh/[PhNNPhy-, with a cathodic
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peak at -1.81 V vs. Ag/AgNO3 and an anodic peak at -1.74 V, and an irreversible cathodic

peak at -2.35 V corresponding to the one-electron reduction of [PhNNPhy- to [PhNNPh]2, which is in agreement with the irreversible cathodic peak observed at -2.35 V in CV

studies of Ph(O)NNPh.108 The results of the CV studies conducted by the Lessard group
are

in

close

agreement with

earlier reported

CV

studies

for PhNO,109-111

Ph(O)NNPh,109,110,112,113 and PhNNPh.109,112,114

Ottenwaelder and coworkers conducted CV studies on free ArNO molecules p-

RC6H4NO, where R = H, Cl, Br, NMe2, or NO2. One reversible redox couple,
ArNO/[ArNO]’-, with a half-wave potential (E1/2) ranging from -1.69 to -0.93 V vs.

ferrocenium/ferrocene (Fc+/Fc), was detected in the CV of all the free ArNO molecules
studied, where -1.69 V (the most negative E1/2) corresponded to the molecule with R =

NMe2, which is the most electron-donating substituent of those studied, and -0.93 V (the

least negative E1/2) corresponded to the molecule with R = NO2, which is the most electron
withdrawing substituent. A second reversible redox couple, Ar(O)NNAr/[Ar(O)NNAr] ^-,
with an E1/2 ranging from -1.86 to -1.33 V vs. Fc+/Fc was also detected in the CV studies

of all the free ArNO molecules except R = NMe2, where the most negative E1/2

corresponded to PhNO (R = H) and the least negative E1/2 corresponded to the molecule
with the most electron-withdrawing substituent (R = NO2).115 The redox potentials are

clearly dependent on the para substituent.
In addition to performing CV studies on certain free ArNO, Ottenwaelder and

coworkers performed extensive CV studies on Cu complexes containing the studied ArNO
species as ligands, as well as the ancillary neutral ligand TMPD (N,N,N',N'- tetramethyl-

1,3-propanediamine) and the counteranion F3CSO3- (triflate). It is important to note that
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Cu is in the +1 oxidation state in its complex with TMPD, [Cu(TMPD)(MeCN)](F3CSO3),
before it reacts with ArNO to form Cu/ArNO adducts. In the Cu/ArNO complex with R =
NMe2, Cu remains in the +1 oxidation state and the ArNO is considered a neutral ligand.
However, in the Cu/ArNO complexes with R = H, Cl, or Br, Cu is oxidized to the +2

oxidation state and ArNO is reduced to the radical monoanion ArNO ’’. Additionally, the
Cu/ArNO complex with R = NO2 is a dinuclear species, [TMPDCun(w - n2: n2-PhNO2-)(« F3CSO3)CuIITMPD](F3CSO3), in which both Cu ions are in the +2 oxidation state and

ArNO is reduced to a dianion [ArNO]2-. In the CV studies of the Cu/ArNO complexes, one

irreversible cathodic peak was detected for all the complexes studied with E1/2 values

ranging from -1.05 to -0.72 V vs. Fc+/Fc, where the most negative E1/2 (-1.05 V)
corresponded to R = NMe2 and the least negative E1/2 (-0.72 V) corresponded to R = NO2.
In the E1/2 range of -1.75 to -1.17 V vs. Fc+/Fc, a quasireversible redox couple was detected

for all the Cu/ArNO complexes except for that containing PhNO, (when R = H, a second

irreversible cathodic peak was determined instead) where the most negative E1/2
corresponded to R = NMe2 and the least negative E1/2 corresponded to R = NO2.
Ottenwaelder’s group proposed that this quasireversibility is a result of the dissociation of

ArNO from Cu, since the E1/2 values are very similar to the ones they obtained for the
second reversible redox couple in the CV of free ArNO. Lastly, in the E1/2 range of -0.36

to -0.11 V vs. Fc+/Fc, a quasireversible redox couple was detected for all the Cu/ArNO

complexes, where once again the most negative E1/2 corresponded to R = NMe2 and the
least negative E1/2 corresponded to R = NO2.115 Just as in the CV of free ArNO, the redox
potentials in the CV of Cu/ArNO complexes are dependent on the para substituent of

ArNO, with redox processes occurring at more negative potentials when the para
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substituent is an electron-donating group and at less negative potentials when the para
substituent is an electron-withdrawing group.
4.3 Background on Electrochemical Studies for Cobalt Aromatic Diimine Complexes
Numerous studies of ruthenium complexes with redox-active aromatic diimine

ligands have been reported (see Chapter II, Section 2.2 for details on the redox activity of
bpy), but there have been comparatively fewer reports on the studies of cobalt complexes
with similar types of redox-active ligands. However, some studies have reported interesting

electrochemical data on cobalt complexes of bpy, 2,2':6',2''-terpyridine (tpy), 1,10-

phenanthroline (phen), and derivatives of these ligands that are useful points of reference
to our electrochemical studies.

CV studies of the complexes Co(bpy)32+ and Co(tpy)22+ (as well as of similar
complexes containing substituted analogs of the bpy and tpy ligands) were performed by

Conradie and coworkers. These studies showed three reversible redox couples for each
complex. Based on density functional theory (DFT) calculations, one redox couple was
assigned as Co(III)/Co(II), which is a Co-based redox process, in the E1/2 range of -0.266

to -0.081 V vs. Fc+/Fc, where E1/2 becomes less negative as the substituent on bpy or tpy

becomes less electron-donating; a second redox couple was assigned as Co(II)/Co(I),
indicating another Co-based redox process, in the E1/2 range of -1.673 to -1.189 V vs.

Fc+/Fc, where E1/2 becomes less negative as the substituent on bpy or tpy becomes less
electron-donating; and a third redox couple was assigned as Co(I)/Co(I)(L^’), indicating a

ligand-based redox process in which a Co(I) complex undergoes a reduction such that one
of the initially neutral bpy or tpy ligands (“L”) is reduced to a radical anion, but the +1

oxidation state of Co remains the same, in the E1/2 range of -2.141 to -2.032 V vs. Fc+/Fc,
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where, again, E1/2 becomes less negative as the substituent on bpy or tpy becomes less

electron-donating.116,117 Conradie’s group also conducted CV studies of Co(phen)32+ and
similar complexes bearing substituted phenanthroline ligands. In these cases, the authors

were able to identify an analogous set of three reversible redox couples, although the
reduction of Co(5-nitro-phen)32+ indicated irreversible behavior. DFT calculations

indicated that the irreversibility was due to ligand-based reduction.116,118
Fontecave and coworkers performed CV studies on eight Co(tpy)22+ complexes

with varying substituents on the tpy ligands. Based on DFT calculations, the authors were

able to assign one redox couple for each complex as Co(II)/Co(I), indicating a Co-based
redox process. This redox couple was also assigned as being reversible for all eight
complexes studied. On the other hand, a second redox couple, which appeared at more

negative potentials than the other redox couple, was assigned as either reversible or
irreversible depending on the ligand. Based on DFT calculations, the second redox couple

was assigned by the authors as a ligand-based redox process in which a Co(I) complex
undergoes a reduction such that one of the substituted tpy ligands is reduced to a radical

anion but the +1 oxidation state of Co remains the same.116,119 As with the CV studies
conducted by Conradie and coworkers,117 these authors were also able to propose that

ligand-based redox processes tend to occur at more negative potentials than those for Co
based redox processes.

Other CV studies were conducted by MacFarlane and coworkers on Co(bpy)32+ in
various organic solvents and ionic liquids.116,120 Like Conradie’s group,117 the authors were

able to assign the Co(III)/Co(II) redox couple as being reversible. The second redox couple

Co(II)/Co(I), in contrast to that studied by Conradie and coworkers,117 was assigned by
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these authors as being irreversible. The Co(II)/Co(I) redox couple identified by MacFarlane

and coworkers appeared at more negative potentials than their Co(III)/Co(II) redox couple.

The authors hypothesized that the irreversibility of the Co(II)/Co(I) redox couple is due to
irreversible dissociation of the bpy ligand from the short-lived Co(I) species Co(bpy)3+. To

test this hypothesis, these authors conducted a CV experiment on Co(bpy)32+ in the

presence of excess bpy. Their hypothesis was supported by the observation under these
conditions of a reversible Co(II)/Co(I) redox couple.116,120

4.4 Results and Discussion

Our redox activity studies of the [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 complex salt,
in addition to the homoleptic [Co{Ph(O)NN(O)Ph}4](PF6)2 complex salt, using CV and

UV-visible spectroelectrochemistry were performed in collaboration with Dr. Jerry

Mundell and Prof. Mekki Bayachou of Cleveland State University, and have been
published in Inorganica Chimica Acta.116
A CV measurement116 of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 that was taken in the

cathodic direction (the potential swept negatively) at a sweep rate of v = 100 mV/s is
depicted in Figure 21. This CV shows two redox couples, where the first redox couple is

indicated as 1C/1A, the second redox couple indicated as 2C/2A, “C” standing for the
cathodic peak and “A” standing for the anodic peak. The first redox couple 1C/1A has a

peak potential separation AEp (the difference between the cathodic peak potential and its

corresponding anodic peak potential106) of 40 mV and a half-wave potential E1/2 (the
halfway potential between a cathodic peak and its corresponding anodic peak106) of -560

mV. The second redox couple 2C/2A was calculated as having AEp = 116 mV and E1/2 = -

1018 mV. The peak dip that is shown in Figure 21 around -1.000 V is likely either a pre
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equilibrium or an impurity. In addition, the CV in Figure 21 shows a signal at a more
negative potential (-2.500 V). This signal is proposed to be due to a reduction of the solvent

DMF and/or a reduction of our supporting electrolyte nBu4NPF6 occurring at the Pt working
electrode, since this signal was also observed when performing electrochemical cleanings

of the Pt working electrode in a blank nBu4NPF6 solution.116

Figure 21: CV of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 at v = 100 mV/s with potential swept
in negative (cathodic) direction.
CV data for [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 were obtained at sweep rates

ranging from 100 to 500 mV/s. Cathodic and anodic peak currents (ip,c and ip,a respectively)
were plotted vs. v1/2 for both redox couples, and the shape of these plots was compared to
that predicted by the Randles-Sevcik equation, ip = 0.4463(F3/RT)1/2n3/2AD1/2 C* v1/2, where

F is Faraday’s constant, n is the number of electrons transferred in the redox process, A is
the area of the working electrode’s surface, D is the analyte’s diffusion coefficient, and C*
is the analyte’s concentration in the bulk solution. This equation predicts that a plot of ip

vs. v1/2 will be linear, and such linearity was indeed observed in the plots, with the exception
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of the outlier point at 200 mV/s for the first redox couple.116 The linear plots indicated

diffusion control of the analyte [Co(bpy){Ph(O)NN(O)Ph}2]2+ in electrolyte solution,

although with a nonzero intercept that is proposed to be due to a portion of current arising
from non-redox processes.121 The plots for both redox couples116 are shown in Figure 22.

For each redox couple, AEp increased gradually as v increased, which is more noticeable
for the first redox couple. Average AEp as well as E1/2 values were calculated, along with

their standard deviations, over all v studied (except for the outlier at 200 mV/s for the first
redox couple)116 and are presented in Table II.
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Figure 22: Randles-Sevcik plots for both redox couples.
Redox couple

1

2

Average AEp (mV)

68 ± 22

135 ± 12

Average E1/2 (mV)

-567 ± 4

-1016±2

Table II: Average AEp and E1/2 values for both redox couples.
The two redox couples observed in our CVs of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2
are proposed to correspond to quasireversible electron-transfer reactions, falling between

being fully reversible and fully irreversible. Both redox couples had average peak potential
separations (AEp) that were significantly greater than 58 mV, which is the value expected

for fully reversible redox couples at ambient temperature.122,123 As mentioned previously,

58

for both redox couples, kEp increased gradually as v increased, another behavior that is

predicted for quasireversible couples.122,124 Importantly, quasireversibility behavior was
also determined for the two redox couples observed in the CVs of the homoleptic

[Co{Ph(O)NN(O)Ph}4](PF6)2 complex salt.116 A plausible reason why quasireversibility is

observed in the heteroleptic [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 complex salt would be the

dissociation of Ph(O)NN(O)Ph or bpy ligands upon reduction,116 which are similar to CV

results for Co(bpy)32+ that were obtained by MacFarlane and coworkers.120 However, it is
unlikely that this ligand dissociation is fully irreversible because there was no evidence of

linearity between peak potential and the logarithm of v.123,125 We propose that the first
redox couple observed for [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 corresponds to a Co-based

reduction of Co(II) to Co(I), based on recent DFT calculations of Co(II) complexes
containing polypyridyl and phenanthroline ligands that were performed by Conradie and

coworkers,117,118 whereas the second redox couple is proposed as corresponding to a ligand

based reduction on either the Ph(O)NN(O)Ph or the bpy ligand with the Co metal center in
the +1 oxidation state.116 MacFarlane’s group showed that the Co(II)/Co(I) redox couples

with bpy ligand dissociation appeared at more negative potentials (-1210 to -1400 mV)120
than those observed in our CVs of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 and even in the CVs
of [Co{Ph(O)NN(O)Ph}4](PF6)2.116 This suggests that the dissociation of Ph(O)NN(O)Ph
is more likely than the dissociation of bpy. Furthermore, Conradie and coworkers117,118 and
Fontecave and coworkers119 were also able to observe the Co(II)/Co(I) redox couples for

their Co complexes containing aromatic diimine ligands occurring at more negative
potentials

than

those

observed

for

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2

and

[Co{Ph(O)NN(O)Ph}4](PF6)2. The strong electron-withdrawing nature of azodioxides is
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proposed to make the reduction of our complex more thermodynamically favorable, and
thus occurring at less negative electrode potentials, than that of complexes containing
aromatic diimine ligands alone.116

In

order

to

further

understand

the

redox

behavior

of

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2, UV-visible spectroelectrochemical studies were
performed.

Absorbance

spectra116

at

various

potentials

were

taken

for

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2. Figure 23 shows the overlaid absorbance spectra. As
it can be seen in Figure 23, there is an absorbance peak at 305 nm before performing

electrolysis. However, when performing electrolytic reduction at a potential of -2071.6

mV, the peak at 305 nm disappears and a new absorbance peak at 284 nm appears.
Following electrolysis, the reoxidation process shows the peak at 284 nm disappearing
slowly with the absorbance peak at 305 nm reappearing, albeit with less intensity than the

initial 305 nm absorbance peak. Since the initial absorbance spectrum was partially, but
not fully, recovered upon reoxidation, this is indicative of quasireversible redox behavior,

consistent with that observed in the CV studies of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2. In
addition, we propose that the ligand-based redox activity that was proposed in the second
redox couple from the CV studies yields the absorbance peak at 284 nm, though some

decomposition seemed to occur in this doubly reduced species, which is why the recovery
of our complex is incomplete upon reoxidation.116 Based on these results, we propose that
the ligand-based redox activity corresponds to a reduction in the Ph(O)NN(O)Ph ligand as

opposed to the bpy ligand. This conclusion is based on spectroelectrochemical studies of
the ruthenium complex Ru(bpy)32+ conducted by Heath and coworkers: their results

suggest that the doubly reduced form of that complex is [(Ru2+)(bpy)(bpy-)2], with a n ^
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n* transition of the unreduced bpy ligand responsible for the absorbance peak at 296 nm.126
This wavelength is reasonably close to the peak observed at 284 nm for our doubly reduced

species, and we thus propose it is due to absorbance by an unreduced bpy ligand.
Additionally, UV-visible spectroelectrochemical studies of the homoleptic complex

[Co{Ph(O)NN(O)Ph}4](PF6)2, which were performed under very similar experimental
conditions as [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2, had shown its electrolysis being mostly
reversible, suggesting that [Co{Ph(O)NN(O)Ph}4](PF6)2 undergoes the same type of

process as [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2. Therefore, if ligand-based reduction is
occurring, it is likely that the Ph(O)NN(O)Ph ligand is being reduced in both complexes,
since the homoleptic species [Co{Ph(O)NN(O)Ph}4](PF6)2 does not contain a bpy ligand
that could also be reduced.116

Figure 23: Spectroelectrochemical studies of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 in which
absorbance spectra were taken at various potentials.
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4.5 Experimental Methods
Electrochemical

studies

of

our

novel

complex

salt

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 were conducted using a WaveNow potentiostat from

Pine Instrument Company.116 For the CV studies, the working electrode, the electrode
where the electrochemical event of interest takes place,106 was a platinum disk,116 the
counter electrode, which is responsible for completing the electrical circuit with the

working electrode,106 used was a platinum wire,116 and the reference electrode, which is
commonly used as a point of reference against which other electrode potentials can be
measured,106 used was technically a silver (Ag) pseudoreference electrode.116 In most

cases, Ag+/Ag reference electrodes, in which Ag+ is present in aqueous solution, are
utilized in systems with organic solvents. Unfortunately, when working with these types

of electrodes, there is the possibility of this aqueous solution leaking into the solution
containing the analyte.106 Since we wished to perform these experiments under anhydrous

conditions, we instead employed a silver pseudoreference electrode in addition to an
internal standard.106 Ferrocene, (n 5-C5H5)2Fe (abbreviated Fc), was used as our internal

standard with the ferrocenium/ferrocene (Fc+/Fc) redox couple as the reference potential
due to its convenience, reproducibility, and allowability for a comparison of reduction

potentials.127 For UV-visible spectroelectrochemistry studies, a platinum honeycomb

electrode from Pine Instrument Company was used as the working electrode and
absorbance spectra were obtained from a Shimadzu UV-2600 spectrometer. All potentials

in this study are reported in relation to the ferrocenium/ferrocene (Fc+/Fc) redox couple as
internal standard. The solvent that was employed in our electrochemical studies was

dimethylformamide (DMF).116 Not only were our complex and supporting electrolyte both
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highly soluble in DMF, but this solvent was shown to be stable toward redox processes in

the potential windows we worked with. Even though [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2

was synthesized in acetonitrile (MeCN), we opted not to use this solvent in our
electrochemical studies because there was evidence of MeCN reduction at the more
negative potential windows that were scanned. Importantly, DMF was degassed by

sparging with nitrogen gas to remove O2. The presence of O2 in an electrochemical

experiment can result in the formation of the oxygen radical anion O2’~ (superoxide) from
the reversible, one-electron reduction of O2.106 Therefore, O2 can affect an analyte’s
response in an electrochemical study. DMF was also dried over activated 4 A molecular

sieves. Lastly, the supporting electrolyte used in our electrochemical studies was 0.1 M
nBu4NPF6.116 Organic solvents, even highly polar ones like DMF, have a lower
conductivity than water. Therefore, to increase the conductivity of the DMF solutions of

our complex, the use of a supporting electrolyte was necessary. The salt nBu4NPF6 is
considered a good supporting electrolyte not only for the noncoordinating behavior of its

PF6- anion, but also because it is highly soluble and stable in polar organic solvents like

DMF.106
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CHAPTER V
THE COBALT(II) BIPYRIDYL/DIPHENYLAZODIOXIDE COMPLEX SALT AS A

CATALYST IN ALLYLIC AMINATION REACTIONS

5.1 Rationale
An important application of transition metal complexes containing redox-active

ligands is in the catalysis of organic reactions.128 We were interested to see if
[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 possessed novel reactivity due to its unusual trigonal
prismatic coordination geometry and the evidence of redox activity129 in its azodioxide

ligands.

Specifically,

we

were

interested

in

the

investigation

of

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 as a potential catalyst in allylic amination reactions,
which involve the synthesis of allylic amines, since these reactions are of major utility.
Allylic amines can act as advanced reaction intermediates in reactions such as asymmetric
isomerization130 and ring-closing metathesis131.132 Additionally, allylic amines can serve

as starting materials in the syntheses of alkaloids,133 carbohydrates and their derivatives,134
and a- and P-amino acids.135 Additionally, natural products containing allylic amine

moieties are known.136,137 The structure of allylamine, the simplest allylic amine, is shown

in Figure 24.
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allylamine

Figure 24: Structure of allylamine.
In particular, as was previously mentioned in Chapter I, Section 1.1, transition
metal complexes can be useful catalysts in the pharmaceutical industry, and allylic

amination is itself important in the pharmaceutical industry since there are drugs that

contain allylic amine moieties.137 Examples of such pharmaceuticals are cinnarizine,138 an
antihistamine used to primarily treat motion sickness; terbinafine,139 an antifungal used to

treat ringworm and athlete’s foot (which is on the WHO List of Essential Medicines as of
2019);140 lisuride,141 a drug used to treat Parkinson’s disease and migraines; and

vigabatrin,142 a drug used to treat seizure disorders in infants. The two types of allylic

amination reactions that are especially important for applications,

including

pharmaceutical applications, are the direct allylic amination of alkenes, which may also
involve carbon-carbon (C-C) double-bond transposition, and nucleophilic allylic

substitution.136

5.2 Types of Allylic Amination
5.2.1 Direct Allylic Amination/C-C Double-Bond Transposition
This type of allylic amination involves the breaking of a C-H bond, and also

involves the movement of a C-C double bond from its original position in the original

alkene substrate. Because of the bond strength of the C-H bond to be broken, the direct
allylic amination of alkenes can be challenging to accomplish. This type of allylic

amination is of interest because it has been shown to be useful in the synthesis of
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polyfunctional amines.136 Importantly, the direct allylic amination of alkenes has been
shown to be regioselective143-147 (one isomer of all the possible isomers produced is the

major product of the reaction148), in which the N atom of the amine substrate adds to the

less substituted carbon of the original alkene carbons.149 No additional products derived
from the alkene are usually observed in these reactions.143-147 A general reaction scheme

for direct allylic amination/C-C double-bond transposition reactions is shown in Figure
25.136

R'NX

HX

*R and R’ represent alkyl or aryl groups
*X represents an electronegative group

Figure 25: General reaction scheme for direct allylic amination/C-C double-bond
transposition reactions.
Most importantly, the direct allylic amination of alkenes has been shown to be
catalyzed by the azodioxide complex salt [Fe{Ph(O)NN(O)Ph}3](FeCl4)2 prepared by

Nicholas’ group (refer to Figures 8a and 8b in Chapter I, Section 1.6).146,150,151 Nicholas’
group proposed that the complex cation [Fe{Ph(O)NN(O)Ph}3]2+ was formed in situ when
FeCl2

or FeCl3

was used

as

a

precatalyst.152

The

isolated

complex

salt

[Fe{Ph(O)NN(O)Ph}3](FeCl4)2 was itself shown to be a competent catalyst for the
particular reaction depicted in Figure 26,150 where the reaction involved a 10 mol% catalyst

loading of [Fe{Ph(O)NN(O)Ph}3](FeCl4)2, a reaction temperature ranging from 70-100°C,
and a reaction solvent of 1,4-dioxane.146
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cat. [Fe{Rh(O)NN(O)Ph}3](FeCI4)2
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Figure 26: Allylic amination/C-C
[Fe{Ph(O)NN(O)Ph}3](FeCl4)2.

double-bond

transposition

k- *
catalyzed

by

The Nicholas group proposed a partial catalytic cycle150 shown in Figure 27 for the

reaction of Figure 26. The first step in the cycle is the dechelation of an azodioxide ligand
from the catalyst [Fe{Ph(O)NN(O)Ph}3](FeCl4)2, forming a five-coordinate reaction

intermediate. After dechelation takes place, an alkene coordinates to the intermediate,
yielding a n-complex adduct. The allyl hydroxylamine intermediate then forms as a result
of the migration of the PhNO unit in the adduct to the alkene. During this step, a nitroso

ene reaction (a form of the Alder ene reaction in which the enophile is a nitroso
compound151,153) takes place between an azodioxide ligand with an uncoordinated oxygen

atom and the n2-coordinated alkene (meaning two C atoms of an alkene ligand are bonded
to the metal center),154 indicating that this catalysis operates through an “on-metal”

mechanism.136,146,150,151 An on-metal mechanism is one in which PhNO (or its azodioxide
dimer) remains coordinated to the metal while reacting with the alkene substrate, whereas
an “off-metal” mechanism is one in which free (uncoordinated) PhNO is formed as an
intermediate and acts as the main aminating agent during the catalysis.136,151 The allyl

hydroxylamine that was formed is then deoxygenated by an Fe(II) species, resulting in the
formation of the allylic amine and an oxidized bimetallic Fe(III) species. The catalyst can
then be regenerated by the reduction of the bimetallic Fe(III) species by

phenylhydroxylamine (PhNHOH). It is important to note, however, that Nicholas’ group
observed the byproducts azoxybenzene, Ph(O)NNPh, and azobenzene, PhNNPh, both of
which are deoxygenation products of PhNO or azodioxide, when they conducted a GC-MS
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analysis of their reaction mixture.146,150,151 These deoxygenation reactions compete with
the desired allylic amination reaction, and it has been reported that suppression of such side
reactions is challenging, resulting in a decrease in the allylic amine yield.136 Fortunately,

the catalyst [Fe{Ph(O)NN(O)Ph}3](FeCl4)2 was shown to improve the allylic amine yield
and reduce the amounts of deoxygenation byproducts produced compared to a

molybdenum(VI) dioxo complex143 that Nicholas’ group earlier investigated as a catalyst
for this type of reaction,136 indicating that either the presence of Fe(II) rather than Mo(VI),
the azodioxide ligand in the catalyst [Fe{Ph(O)NN(O)Ph}3](FeCl4)2, or both makes this
catalyst more effective.

Figure 27: Partial catalytic cycle for the direct allylic amination of an alkene using
[Fe{Ph(O)NN(O)Ph}3](FeCl4)2 as a catalyst.
5.2.2 Nucleophilic Allylic Substitution

Nucleophilic allylic substitution is one of the most simple and direct types of allylic

amination.136 These reactions have shown great efficiency and flexibility.155 Most

nucleophilic allylic substitution reactions involve the use of a substrate that contains a good
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leaving group. Since allylic alcohols contain a poor leaving group, they were initially not
used as substrates. A transition metal catalyst is usually required to activate such

substrates.156 Recently, however, there has been a growing interest in the use of allylic
alcohols as substrates for nucleophilic allylic substitutions due to their ready availability136

and their ability to reduce byproduct formation, since nucleophilic allylic substitution on
an allylic alcohol will yield H2O as the other stoichiometric product, constituting a greener

and more sustainable process.155,156 A general reaction scheme for nucleophilic allylic

substitution reactions is depicted in Figure 28.136

*R and R’2 represent alkyl or aryl groups
*X represents an electronegative group

Figure 28: General reaction scheme for nucleophilic allylic substitution reactions.
Transition metal complexes have been shown to act as stereo-, regio-, and

enantioselective catalysts for the nucleophilic allylic substitution of alcohols.156 The most
commonly used transition metal catalysts for the nucleophilic allylic substitution of allylic
alcohols contain palladium or iridium,155 which are 2nd- and 3rd-row transition metals,

respectively. However, transition metal catalysts containing cheaper and more Earthabundant 1st-row transition metals, especially iron and nickel, have been increasingly

used.157 In addition to the examples already mentioned, the iron complex Fe(CO)3{ n4-

(CH2)4(SiMe3)2C5O} has proven to be an active catalyst in the one-pot synthesis of the
allylic amine drug cinnarizine,138 whose synthesis involves the nucleophilic allylic
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substitution

of

the

allylic

alcohol

cinnamyl

alcohol

with

the

amine

1-

benzhydrylpiperazine.158

5.3 Results and Discussion
5.3.1 Direct Allylic Amination/C-C Double-Bond Transposition
Since Nicholas’ group was able to show that an azodioxide complex can act as an

active catalyst in direct allylic amination/C-C double-bond transposition reactions, we
were interested in studying the reactivity of our newly synthesized heteroleptic azodioxide
complex by assessing its catalytic ability in these types of reactions.

The effective catalysis of the direct allylic amination of 2-methyl-2-pentene and 2-

methyl-2-hexene with PhNHOH by [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 has been
demonstrated and published in Results in Chemistry.151 We decided to study trisubstituted,
unsymmetrical alkenes as substrates because Nicholas’ group showed that such substrates

gave the best allylic amine yields and regioselectivity when their catalyst was used.146 The
catalytic scheme151 is demonstrated in Figure 29. When R = H, the catalytic turnover

number is 4.0 with an isolated yield of the allylic amine product of 40%, whereas when R
= CH3, the catalytic turnover number becomes 1.4 with an isolated yield of only 14%.

Other reaction conditions were attempted (different solvents, reaction times, reaction
temperatures), but the conditions depicted in Figure 29 gave the best results. It is important
to note that the allylic amine products are racemic mixtures of their R and S enantiomers

since this catalysis is not enantioselective but regioselective. Importantly, the catalysis of
the

direct

allylic

amination of alkenes

in which homoleptic

[Co{Ph(O)NN(O)Ph}4](PF6)2 was the catalyst gave very similar results.
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The turnover number for a catalyst refers to the average number of catalytic cycles

completed before the catalyst becomes degraded.159 As it can be seen in Figure 29, the
reported turnover numbers for our catalytic reactions are low, suggesting that this limited

catalytic efficiency may be caused by a side reaction or reactions of the catalyst. It is very

likely that the azodioxide ligand is undergoing deoxygenation during the reaction since

GC-MS analysis of a diethyl ether extract of the reaction mixtures showed the presence of

both Ph(O)NNPh (m/z 198) and PhNNPh (m/z 182). As was previously mentioned,
Nicholas’ group also detected the deoxygenation products Ph(O)NNPh and PhNNPh when
using their complex salt [Fe{Ph(O)NN(O)Ph}3](FeCl4)2 as a catalyst in the direct allylic

amination of alkenes. 146,150,151 Nicholas’ group reported a turnover number of 8.8 for the
direct allylic amination of 2-methyl-2-pentene with PhNHOH, although they calculated
this number based on a yield from their GC analysis as opposed to an isolated yield as we

did.146 However, they did not report a yield for the direct allylic amination of 2-methyl-2hexene with PhNHOH. Our observation of these byproducts not only further confirms the

difficulty in suppressing their formation, but suggests, on the basis of our lower turnover
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numbers, that their formation is possibly more significant in our reactions.151
We performed an important control experiment to investigate the mechanism of our
catalytic reactions. In particular, we were interested to find out if this catalysis operated by
an “off-metal136” or “on-metal136” mechanism. In order to distinguish between these two

main mechanistic types, a Diels-Alder trapping experiment151 was performed by treating
2,3-dimethyl-1,3-butadiene with our catalyst [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 under the
solvent and temperature conditions used in our catalytic reactions. As opposed to an allylic

amination product of 2,3-dimethyl-1,3-butadiene, GC-MS analysis of the reaction mixture

revealed the formation of a Diels-Alder cycloadduct of PhNO and 2,3-dimethyl-1,3butadiene (m/z 189). This cycloadduct formation suggests that an “off-metal” mechanism
for

the

catalysis

of

the

direct

allylic

amination

of

alkenes

by

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 is likely operative, in which free PhNO, rather than a
coordinated azodioxide, acts as the aminating agent. The Diels-Alder trapping

experiment151 is depicted in Figure 30. In contrast, when Nicholas’ group performed the
analogous Diels-Alder trapping experiment with [Fe{Ph(O)NN(O)Ph}3](FeCl4)2, they
observed the allylic amination product of 2,3-dimethyl-1,3-butadiene, not its cycloadduct

with PhNO. This suggests that, in contrast to our catalytic reactions, the allylic amination

of alkenes catalyzed by [Fe{Ph(O)NN(O)Ph}3](FeCl4)2 proceeds by an “on-metal”
mechanism in which free PhNO is not generated as an intermediate. 136,146,150,151

Figure 30: Diels-Alder trapping experiment with 2,3-dimethyl-1,3-butadiene.
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With the “off-metal” mechanism being suggested by the trapping experiment

described above, we were able to propose a partial catalytic cycle151 for the catalysis of the
direct allylic amination of alkenes by [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2. This partial

catalytic cycle151 is shown in Figure 31. In this proposed cycle, uncoordinated PhNO,

which forms from an azodioxide ligand dissociated from cobalt, reacts with an alkene

substrate in a nitroso-ene reaction to yield a hydroxylamine. This hydroxylamine is then
reduced to an allylic amine by Co(II), forming a bimetallic Co(III) complex with a bridging

oxido ligand. In addition to the formation of the deoxygenation products Ph(O)NNPh and
PhNNPh, another possible explanation for the low turnover number we observed for these
reactions is an irreversible decomposition reaction of the bimetallic Co(III) complex

(LnCoIII-O-CoIIILn) with water, leading to the formation of a Co(III) oxide or hydroxide,
which are both thermodynamically stable. In the final step of our proposed partial catalytic

cycle, PhNHOH is dehydrogenated by the bimetallic Co(III) complex in order to yield H2O
and regenerate PhNO and Co(II).
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Figure 31: Proposed partial catalytic cycle for the direct allylic amination of alkenes by
[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2.
Since a higher yield and turnover number resulted from the catalysis of the direct

allylic amination of 2-methyl-2-pentene with PhNHOH, the characterization of its allylic

amine reaction product C12H17N will be discussed further. The allylic amine was
characterized by GC-MS and 1H NMR spectroscopy.
After removing nonvolatile cobalt-containing species from our reaction mixture via

a silica gel pipette column, GC-MS analysis was performed on a diethyl ether extract of
our crude reaction mixture to identify the organic products that were formed.151 As was
previously mentioned, in addition to the desired allylic amine product C12H17N (m/z 175),

the byproducts Ph(O)NNPh (m/z 198) and PhNNPh (m/z 182) were also identified. The m/z

74

(mass-to-charge ratio) value reported for each product corresponds to its molecular ion
peak (M+). A molecular ion is formed when one electron from a molecule is removed using
an ionization source such as electron ionization in a mass spectrometer and has the same

molecular weight as the initial molecule.160 Each reaction product peak in the gas
chromatogram of the crude reaction mixture was identified by comparing each peak’s

corresponding experimental mass spectrum to that in a NIST library and by extracting ion
chromatograms, where extracted ion chromatograms are plots of signal abundance versus

retention time at selected m/z values.161 The experimental mass spectrum of our allylic

amine reaction product C12H17N is depicted in Figure 32a, and the experimental mass

spectra of the byproducts PhNNPh and Ph(O)NNPh are reported in Figures 32b and 32c,
respectively. Most of the weak signals at m/z values greater than the molecular ion peaks
in the mass spectra in Figure 32 possibly represent minor impurities from the GC column

and/or mass spectrometer or noise. The experimental gas chromatogram of our crude
reaction mixture with the allylic amine reaction product peak as well as the Ph(O)NNPh

and PhNNPh byproduct peaks labeled is shown in Figure 33. Figure 33 shows that the
retention time of the allylic amine was identified at 15.754 min and that the retention times

of the byproducts PhNNPh and Ph(O)NNPh were identified at 5.217 min and 8.125 min,

respectively. The unlabeled peaks in the gas chromatogram in Figure 33 are possibly minor

impurities from the instrument, silicon-containing species from the GC column, or noise.
Once we were able to identify the crude allylic amine reaction product by GC-MS, the next

step was to separate and purify the allylic amine by preparative column chromatography
before taking its 1H NMR spectrum.151

75

Figure 32: Experimental mass spectra of (a) allylic amine product (b) PhNNPh (c)
Ph(O)NNPh.
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Figure 33: Experimental gas chromatogram of crude reaction mixture from the catalysis of
the direct allylic amination of 2-methyl-2-pentene with PhNHOH.
The experimental 1H NMR spectrum of our allylic amine reaction product C12H17N
is depicted in Figure 34c. Its spectrum is compared to the experimental 1H NMR spectra

of the starting materials 2-methyl-2-pentene (Figure 34a) and PhNHOH (Figure 34b). It

can be seen in this comparison that our reaction product’s spectrum mostly contains similar
proton signals from both starting materials, indicating that a reaction product was made

and is possibly an allylic amine.
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methylene
Hs

reaction
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Figure 34: 1H NMR spectra of (a) 2-methyl-2-pentene (b) PhNHOH (c) allylic amine
reaction product.
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Each of the proton signals in the 1H NMR spectrum of the allylic amine product are

worth discussing. For the explanation of the proton signals in the regions 1-6 ppm, I will
refer to the protons in the allylic amine product’s structure that give rise to them as being

attached to carbon atoms that each have a certain number using the numerical scheme
shown in Figure 35, except for the proton attached to the nitrogen atom. For the explanation

of the aromatic proton signals in the 6-8 ppm range, I will refer to the aromatic protons as
ortho, meta, or para. Furthermore, our experimental spectrum was compared to a literature

spectrum146 of the allylic amine product that was reported by Nicholas’ group.

Figure 35: Numerical scheme of carbons in the allylic amine structure.
The proton signal around 1 ppm in the 1H NMR spectrum of the allylic amine
reaction product (Figure 34c) corresponds to the methyl protons that are attached to carbon

5. The splitting of this signal appears to be a triplet. Also, the integration of this peak was
2.9369, which rounded up to the nearest whole number is 3, indicating that 3 protons
generate this signal. The 1 ppm region of the NMR spectrum of the allylic amine is shown

in Figure 36. It is important to note that the expected splitting pattern for this signal is a
doublet of doublets because the 2 protons that are attached to the neighboring carbon 4 are
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not of the same type. In other words, the 2 neighboring protons are in different chemical

environments (chemically non-equivalent), with each proton producing its own signal with
its own chemical shift in a 1H NMR spectrum. With this being said, applying the N + 1 rule

for each of the 2 neighboring, chemically non-equivalent protons, where “N” is the number
of neighboring protons of a certain type, in order to determine the splitting pattern of the

signal around 1 ppm, should have yielded a signal appearing as a doublet of doublets.
(Since there are 2 neighboring, non-equivalent protons, the N + 1 rule needed to be applied
twice, and since there is 1 proton of each of the 2 types in this scenario, the N + 1 rule

yields the number 2 for each application of the rule, meaning the peak splitting is expected
to be a doublet of doublets.) However, a triplet splitting pattern is observed in Figure 36

because the chemical environments of the 2 diastereotopic hydrogens on carbon 4 are very
similar that these hydrogens’ coupling constants with the hydrogens attached to carbon 5
are extremely close in value, and the diastereotopic hydrogens cannot be distinguished at

the level of resolution provided by the 400-MHz NMR spectrometer we used. If the

spectrum had been obtained on an NMR spectrometer with a very high frequency such as

1000 MHz, then the spectral resolution of the signals would be more resolved,162 and the
expected doublet of doublets signal would be observed around 1 ppm. Importantly, the
literature spectrum with which we compared our NMR data also shows a signal with a
triplet splitting pattern at 1.07 ppm (close to the 1 ppm value we observed) with an

integration indicating that 3 protons give rise to this signal.146

80

Figure 36: 1 ppm region of the 1H NMR spectrum of allylic amine product.
The proton signal around 1.66 ppm in the 1H NMR spectrum of the allylic amine
reaction product (Figure 34c) corresponds to the methyl protons that are attached to carbon

2. The methyl protons on carbon 2 are more deshielded than the methyl protons on carbon
5 because these protons are attached to a carbon atom that is adjacent to an sp2-hybridized

carbon. In other words, the protons on carbon 2 are located closer to an sp2-hybridized

carbon atom than those on carbon 5. Since sp2-hybridized carbon atoms are more electron
withdrawing than sp3-hybridized carbon atoms, hydrogen atoms either directly attached to
sp2-hybridized carbon atoms or on nearby sp3-hybridized carbon atoms are less shielded.163
The signal at 1.66 ppm appears to be a singlet, with no splitting pattern. The absence of a

splitting pattern is expected because these methyl hydrogens are not coupled to any
hydrogens on adjacent carbon atoms. The integration of this peak was 2.8211, which when

rounded to the nearest whole number is 3, indicating that 3 protons generate this signal.

The 1.66 ppm region of the NMR spectrum of the allylic amine is depicted in Figure 37.
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The literature spectrum also shows a singlet at around 1.77 ppm (close to the 1.66 ppm

value we observed) with an integration indicating that 3 protons generate this signal.146

Figure 37: 1.66 ppm region of the 1H NMR spectrum of allylic amine product.
The proton signal in the 2 ppm region of the 1H NMR spectrum of the allylic amine
reaction product (Figure 34c) corresponds to the 2 protons that are attached to carbon 4.

The splitting of this signal appears to be a quintet. Also, the integration of this peak was
1.9532, which rounded to the nearest whole number is 2, indicating that 2 protons give rise

to this signal. The 2 ppm region of the NMR spectrum of the allylic amine is shown in

Figure 38. However, the 2 protons attached to carbon 4 are chemically non-equivalent,
meaning that each proton should generate its own NMR signal at its own chemical shift.

Specifically, these protons are known to be diastereotopic, because if the first proton and
then the second proton are replaced by different atoms or groups of atoms, a pair of

diastereomers will result.164 (Diastereomers are types of stereoisomers that are not “mirror
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images” of each other.165) Additionally, the 2 protons attached to carbon 4 are attached to

a carbon atom that is adjacent to a chiral carbon (carbon 3), and protons that are attached
to a carbon adjacent to a chiral carbon (a carbon that is bonded to 4 different atoms or

groups of atoms166) are usually diastereotopic.164 Even though the protons on carbon 4 are
chemically non-equivalent, the signal around 2 ppm in Figure 38 implies that the protons
are chemically equivalent. When chemically non-equivalent protons show up on an NMR

spectrum as being equivalent, this is known as accidental equivalence. Accidental
equivalence can be observed when spectral resolution is limited, and thus insufficiently

sensitive to distinguish diastereotopic protons as being chemically non-equivalent.167
Moreover, the quintet splitting pattern that is observed in Figure 38 does not follow the N

+ 1 rule, which should yield a more complicated multiplet under conditions of sufficient
spectral resolution, because our spectral resolution is limited.162 Furthermore, for the

protons attached to carbon 4, the literature spectrum reveals a multiplet in the chemical

shift range 1.7-1.8 ppm (close to the 2 ppm value we observed) with an integration
indicating that 2 protons give rise to this signal.146 It seems that the 2H multiplet in the

literature spectrum appears to be at a lower chemical shift than the 3H singlet at 1.77 ppm,

whereas in our NMR data, the 2H multiplet appears at a higher chemical shift than the 3H
singlet at 1.66 ppm. Perhaps this difference in chemical shift order between our data and
the literature spectrum is concentration dependent.
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Figure 38: 2 ppm region of the 1H NMR spectrum of allylic amine product.
The proton signal around 3.34 ppm in the 1H NMR spectrum of the allylic amine
reaction product (Figure 34c) likely corresponds to an impurity. It is important to note that

the literature spectrum reported by Nicholas’ group does not show a proton signal around
3.34 ppm. We know the 3.34 ppm signal is not due to residual chloroform NMR solvent

since that residual solvent peak almost always appears as a singlet around 7.26 ppm.168
Also, after comparing the 3.34 ppm signal to other solvents’ NMR proton signals in the

literature,168 we do not believe the 3.34 ppm signal corresponds to a solvent impurity.

Therefore, the only possible explanation for the observance of this signal is due to the

presence of a reaction impurity. The splitting of the 3.34 ppm signal appears to be a triplet.
However, the integration of this peak was 0.9800, which rounded to the nearest whole

number is 1, indicating that 1 proton generates this signal. Interestingly, this 1H triplet

around 3.34 ppm also appears in the 1H NMR spectrum of the 2-methyl-2-pentene
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amination product that was produced in the allylic amination catalysis by the homoleptic
complex salt [Co{Ph(O)NN(O)Ph}4](PF6)2. The 3.34 ppm region of the NMR spectrum of

the allylic amine is shown in Figure 39.

Figure 39: 3.34 ppm region of the NMR spectrum of the allylic amine.
The proton signal in the 4 ppm region of the 1H NMR spectrum of the allylic amine
reaction product (Figure 34c) corresponds to the proton attached to carbon 3. The splitting

of this signal appears to be a triplet. Also, this peak was set as integrating to 1.0000,
indicating that 1 proton gives rise to that signal. The 4 ppm region of the NMR spectrum

of the allylic amine is shown in Figure 40. However, the expected splitting pattern from
the N + 1 rule for this proton signal would be a doublet of doublets, since the 2 neighboring
protons on carbon 4 are chemically non-equivalent. Again, because the spectral resolution

was limited162 and the NMR shows the 2 neighboring protons as being chemically
equivalent, a triplet, as opposed to a doublet of doublets, is observed. For the proton
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attached to carbon 3, the literature spectrum reveals a triplet at around 3.77 ppm (close to
the 4 ppm value we observed) with an integration indicating that 1 proton generates this
signal.146

Figure 40: 4 ppm region of the 1H NMR spectrum of the allylic amine.
The 2 proton signals around 5.18 and 5.31 ppm in the 1H NMR spectrum of the

allylic amine reaction product (Figure 34c) correspond to the 2 protons attached to carbon
1. Two different signals are observed in the 5 ppm region because the 2 protons on carbon

1 are chemically non-equivalent. These protons are known as geminal protons because they
are chemically non-equivalent protons attached to the same carbon atom and interact with

each other to cause splitting of each other’s signal.169 The proton signal around 5.18 ppm

corresponds to the proton that appears closer to the methyl group that is attached to the
carbon adjacent to carbon 1, whereas the signal around 5.31 ppm corresponds to the proton
that appears closer to the amine group attached to carbon 3. The proton on carbon 1 that
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appears closer to the amine group in the allylic amine structure is more deshielded than the
proton closer to the methyl group because the nitrogen atom in the amine is more

electronegative than the carbon atom in the methyl group. The splitting of each signal
appears to be a doublet, which is expected because each of the protons on carbon 1 splits
the other to form doublets based on the N + 1 rule. Also, the integration of the 5.18 ppm
and 5.31 ppm signals were 0.9895 and 1.0000, respectively, indicating that 1 proton
generates each signal. The 5 ppm region of the NMR spectrum of the allylic amine is

depicted in Figure 41. For the protons attached to carbon 1, the literature spectrum reveals
two broad singlets around 5.03 ppm and 5.08 ppm (close to the 5.18 and 5.31 ppm values

we observed) with an integration of each peak indicating that 1 proton generates each
signal.146 It is possible that broad singlets were observed in the NMR spectra taken by

Nicholas’ group because Nicholas’ group used a 300-MHz NMR spectrometer,146 which is

a lower frequency than the 400-MHz spectrometer we used, which can lead to lower
spectral resolution.
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Figure 41: 5 ppm region of the 1H NMR spectrum of the allylic amine.
The proton signals in the chemical shift range 6.85-7.58 ppm correspond to the
aromatic protons on the phenyl group in the allylic amine structure. The signal around 6.85

ppm corresponds to the ortho-protons. This signal appears as a multiplet. Also, the
integration of this peak was 1.9729, indicating that 2 protons generate this signal. The 6.85

ppm region of the NMR spectrum of the allylic amine is depicted in Figure 42a. The signal
in the region 7.0-7.3 ppm corresponds to the para-proton. This signal appears as a
multiplet. Also, the integration of this peak was 0.8591, indicating that 1 proton generates
this signal. The 7.0-7.3 ppm region of the NMR spectrum of the allylic amine is depicted

in Figure 42b. The signal around 7.5 ppm corresponds to the meta-protons. This signal
appears as a multiplet. Also, the integration of this peak was 2.0000, indicating that 2
protons generate this signal. The 7.5 ppm region of the NMR spectrum of the allylic amine
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is depicted in Figure 42c. The literature spectrum reveals the aromatic proton signals being

in the chemical shift range 6.6-7.4 ppm.146

1
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Figure 42: Aromatic proton regions of the 1H NMR spectrum of the allylic amine showing
(a) 6.85 region (b) 7.0-7.3 region (c) 7.5 region.
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5.3.2 Nucleophilic Allylic Substitution

Once we were able to demonstrate that [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 acts as

a competent catalyst in allylic amination/C-C double-bond transposition reactions, I then
decided to investigate the catalytic ability of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 in the
synthesis of drugs containing allylic amine moieties, since catalysis in drug synthesis is
one useful application of transition metal complexes in the medicinal field. Since 1st-row
transition metal catalysts have been increasingly applied to allylic amination reactions,157
and

because

I

wanted

to

expand

the

catalytic

applications

of

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2, I became interested in the possibility of conducting a

one-pot, cobalt-catalyzed synthesis of an allylic amine drug involving an allylic amination
mechanism, whether it be similar or different from the one previously described. A relevant
study,31 which was mentioned in Section 5.2.2, demonstrated that the iron complex
Fe(CO)3{n4-(CH2)4(SiMe3)2C5O} served as a catalyst in the nucleophilic allylic

substitution reaction of cinnamyl alcohol and 1-benzhydrylpiperazine to form the allylic

amine drug cinnarizine.138
As a first approach, I wanted to see if by simply replacing the iron catalyst with the

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 complex salt that we prepared would also act as a
catalyst in that same one-pot cinnarizine synthesis. Preliminary GC-MS results from my

crude reaction mixtures have indicated the desired synthesis of cinnarizine C26H28N2 (m/z

369), although the results also indicated the presence of the two substrates cinnamyl
alcohol (m/z 134) and 1-benzhydrylpiperazine (m/z 251) in excess. The m/z value reported
for each species corresponds to its molecular ion peak (M+). The presence of excess

substrates indicates that there is potential degradation in the catalyst after a certain time.
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Each of the relevant peaks in the gas chromatogram of the crude reaction mixture was

identified by comparing each peak’s corresponding experimental mass spectrum to that in

a NIST library and by extracting ion chromatograms. The experimental mass spectrum of
cinnarizine C26H28N2 is depicted in Figure 43. The weak signals at m/z values greater than

the molecular ion peak at 369 in the mass spectrum in Figure 43 possibly represent minor

impurities from the GC column and/or mass spectrometer or noise. The experimental gas
chromatogram of our crude reaction mixture with the cinnarizine peak as well as the

cinnamyl alcohol and 1-benzhydrylpiperazine peaks labeled is shown in Figure 44. Figure
44 shows that the retention time of cinnarizine was 25.279 min and that the retention times

of cinnamyl alcohol and 1-benzhydrylpiperazine were 7.960 min and 15.031 min,

respectively. The unlabeled peaks in the gas chromatogram in Figure 44 possibly represent

minor impurities from the instrument, silicon-containing species from the GC column, or
noise. Perhaps LC-MS/MS, as opposed to GC-MS, would have been a better choice for the

initial characterization of cinnarizine, since cinnarizine has a boiling point that is too high
to elute at the upper limit of the GC column oven at 280°C. However, our GC-MS system,

unlike our LC-MS/MS system, is equipped with a NIST library of mass spectra, which was
able to reveal to a 95% probability that the mass spectrum corresponding to the GC peak

at 25.279 min in the GC chromatogram in Figure 44 was cinnarizine. The use of the NIST
library, in addition to the extracted ion chromatograms, allowed us to identify the
cinnarizine peak. The preliminary catalytic scheme for the catalysis of the nucleophilic

allylic substitution of cinnamyl alcohol with 1-benzhydrylpiperazine (cinnarizine

synthesis) with [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 as the catalyst is shown in Figure 45.
Other reaction conditions were attempted for this catalysis, but the conditions shown in
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Figure 45 gave the best preliminary results thus far. Work is still being done on the
optimization of the reaction conditions in order to reduce the presence of excess substrates

at the completion of the reaction. Unfortunately, attempts to separate and purify cinnarizine
by preparative column chromatography have been unsuccessful thus far, and therefore

NMR spectra have not yet been acquired to confirm the catalytic synthesis of cinnarizine
and a turnover number and isolated yield have not yet been determined. Hence, it cannot

be reported with certainty that cinnarizine was synthesized. Attempts at column
chromatography are ongoing. The GC-MS results in Figures 43 and 44 do, however, show
some initial promise in the potential application of [Co(bpy){Ph(O)NN(O)Ph} 2](PF6)2 as

a catalyst in the synthesis of allylic amine drugs.

Figure 43: Experimental mass spectrum of cinnarizine.
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Figure 44: Experimental gas chromatogram of crude reaction mixture from the catalysis of
the nucleophilic allylic substitution of cinnamyl alcohol with 1-benzhydrylpiperazine to
form cinnarizine.

Figure 45: Synthesis of the allylic
[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2.

amine

drug

cinnarizine

catalyzed

by

Based on the promising preliminary results from the catalytic synthesis of
cinnarizine, I wished to continue the investigation of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2
as a catalyst in nucleophilic allylic substitution reactions that involve simpler substrates,

so that I could potentially expand the substrate scope for the nucleophilic allylic

substitution reaction involved in the synthesis of cinnarizine.158 The simpler allylic alcohol
substrate under investigation was trans-2-penten-1-ol, whereas the simpler amine
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substrates that were under investigation were piperidine (azacyclohexane) and azepane
(azacycloheptane). Thus far, I have only been able to obtain promising preliminary GCMS results for the catalysis of the nucleophilic substitution of trans-2-penten-1-ol with

piperidine to form the desired allylic amine product C10H19N (m/z 153). The m/z value of

153 corresponds to the molecular ion peak (M+). The potential allylic amine peak in the
gas chromatogram of the crude reaction mixture was identified by comparing its

corresponding experimental mass spectrum to that in a NIST library and by extracting ion
chromatograms. The experimental mass spectrum of the potential allylic amine product
C10H19N is depicted in Figure 46. The weak signals at m/z values greater than the molecular

ion peak at 153 in the mass spectrum in Figure 46 possibly represent minor impurities from
the GC column and/or mass spectrometer or noise. The experimental gas chromatogram of
our crude reaction mixture with the potential allylic amine peak labeled is shown in Figure

47. Figure 47 shows that the retention time of the potential allylic amine product was
10.148 min. The unlabeled peaks in the gas chromatogram in Figure 47 possibly represent
minor impurities from the instrument, silicon-containing species from the GC column, or
noise. The preliminary catalytic scheme, including preliminary optimal reaction conditions
is depicted in Figure 48. The optimization of reaction conditions for this reaction is still

taking place. Unfortunately, as with the catalysis experiments for the synthesis of

cinnarizine, attempts to separate and purify the potential allylic amine product by
preparative column chromatography have been unsuccessful thus far, and therefore NMR

spectra have not yet been acquired to confirm the catalytic synthesis of the desired allylic
amine and a turnover number and isolated yield have not yet been determined. Hence, it

cannot be reported with certainty that the desired allylic amine was synthesized. Efforts at
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column chromatography are still ongoing, but the preliminary GC-MS results show the
potential of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 as a catalyst for two types of allylic
amination: direct allylic amination with concomitant C-C double-bond transposition and

nucleophilic allylic substitution.

Figure 46: Experimental mass spectrum of potential allylic amine product.

Figure 47: Experimental gas chromatogram of crude reaction mixture from the catalysis of
the nucleophilic substitution of trans-2-penten-1-ol with piperidine.
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Figure 48: Nucleophilic allylic substitution of trans-2-penten-1-ol with piperidine
catalyzed by [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2.
5.4 Experimental Methods
5.4.1 General Experimental Considerations

Both direct allylic amination and nucleophilic allylic substitution catalytic reactions

were set up under an air- and moisture-free atmosphere (dry nitrogen) in an MBraun
Labstar Pro glovebox. All glassware was dried at 160°C in an oven before use. Oxygen

was removed from reaction solvents by sparging with nitrogen, and then moisture was
removed from the solvents by passing them through activated alumina in an MBraun MBSPS solvent purification system; air- and moisture-free solvents were kept in the glovebox.

Preparative column chromatography was performed on crude reaction mixtures in a fume

hood.151 The preparation of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 is detailed in Chapter III
and in our synthesis and characterization publication in ACS Omega.170 The starting

materials for the catalytic reactions were purchased from Sigma-Aldrich, Fisher, and
Acros. Using the freeze-pump-thaw method, the liquid reagents were degassed; they were

then dried over activated 4 A molecular sieves. An Agilent GC-MS in which the GC was

equipped with a silica column containing nonpolar groups and a mass spectrometer with
an electron ionization source and a single quadrupole mass analyzer was utilized for our
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GC-MS analyses. A NIST library of electron ionization mass spectra was used to compare
all experimental mass spectra. 1H NMR spectra were acquired for solutions of the purified

allylic amine product from the direct allylic amination catalysis in CDCl3 using a Bruker

Avance III 400 MHz spectrometer.151
5.4.2 GC-MS Method Details

Before running any of our crude reaction mixtures, the GC column was conditioned
for at least 1 hour at a temperature of 280°C to get rid of any analytes or species that

previous GC-MS users might have injected. After conditioning the column, our crude
reaction mixtures were analyzed on the instrument for a total run time of 29.4 min. The
first 5 minutes of the method was dedicated to the solvent eluting before any potential

organic products (solvent delay). The injection volume for each crude reaction mixture into
the instrument was 1 pL. The column flow rate was 1 mL/min. The temperature of the GC

column oven at the beginning and end of the run was 40°C and 280°C, respectively. In
between sample runs, the column was kept at its final 280°C temperature for 10 minutes.
5.4.3 Direct Allylic Amination/C-C Double Bond Transposition Reactions
These reactions were set up in the glovebox, in which 0.073 mmol

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 (10 mol%) was dissolved in 2.5 mL of acetonitrile
(MeCN) and transferred to a Schlenk tube with a stir bar. Then either 1.6 mmol 2-methyl-

2-pentene or 2-methyl-2-hexene (alkene substrates) was added to the Schlenk tube,
followed by a solution of 0.73 mmol phenylhydroxylamine (PhNHOH) in 5 mL MeCN.
PhNHOH was the limiting reagent in these reactions. After the addition of the catalyst and

reagents, the Schlenk tube was sealed with a Teflon stopcock before removing it from the

glovebox. Once the Schlenk tube was removed from the glovebox, it was placed in an oil
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bath at 75°C for 72 hours. Once the reaction was done, the Schlenk tube was removed from
the heated oil bath so that it could cool to room temperature. The reaction solvent MeCN

was removed under reduced pressure, resulting in a brown solid that was extracted with
diethyl ether (Et2O).151

GC-MS was conducted on a small sample of the crude reaction mixture solution
after running it through a miniature column that was composed of roughly 5 cm of silica
gel atop a cotton ball in a Pasteur pipet. The pipet column step was necessary in order to
remove any cobalt metal-containing species from the reaction mixture, since metal

containing species are nonvolatile and would stick to the GC column, fouling it. Preparative
column chromatography was then performed in which the column consisted of silica gel

and the mobile phase was a concentration gradient of petroleum ether and Et2O. The

collected fractions that contained the allylic amine product from column chromatography

were determined by thin layer chromatography and UV light at a wavelength of 254 nm.
These fractions were then combined to remove the solvent under reduced pressure to yield

the allylic amine as a yellow oil.151 The allylic amine identity and purity were confirmed
by 1H NMR spectroscopy as well as comparing to spectral data in the literature.146,151
5.4.4 Diels-Alder Trapping Experiment to Investigate Mechanism of Direct Allylic

Amination Catalysis

The protocol described above for the direct allylic amination reactions (Section

5.4.3) was followed with slight modifications: PhNHOH was not used and 2,3-dimethyl-

1,3-butadiene was used in place of the alkene 2-methyl-2-pentene or 2-methyl-2-hexene.
GC-MS analysis was conducted on a Et2O extract of the crude reaction mixture using the
same method described in Section 5.4.2 in order to identify the reaction product.
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Preparative column chromatography was not conducted, however, for this control
experiment.151
5.4.5 Nucleophilic Allylic Substitution Reactions

This section discusses the experimental details that have thus far given the best
preliminary results. (Refer back to the preliminary catalytic schemes in Figures 45 and 48.)

The

reactions

were

set

up

in

the

glovebox,

in

which

0.03

mmol

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 was dissolved in 5 mL of MeCN and transferred to a
Schlenk tube with a stir bar. Then a solution of either 0.6 mmol cinnamyl alcohol or trans2-penten-1-ol (allylic alcohol substrates) in 5 mL MeCN was added to the Schlenk tube,

followed by a solution of either 0.3 mmol 1-benzhydrylpiperazine or piperidine (amine
substrates) in 5 mL MeCN. (The amounts of reagents and catalyst used were based on the
reported study that demonstrated iron-catalyzed nucleophilic allylic substitution in the

synthesis of cinnarizine.158) The amine is the limiting reagent in these reactions. After the
addition of the catalyst and reagents, the Schlenk tube was sealed with a Teflon stopcock
before removing it from the glovebox. Once the Schlenk tube was removed from the

glovebox, it was placed in an oil bath at 80°C for 72 hours. Once the reaction was finished,
the Schlenk tube was removed from the heated oil bath so that it could cool to room
temperature. The reaction solvent MeCN was removed under reduced pressure, resulting

in a brown solid that was extracted into diethyl ether (Et2O).

GC-MS analysis was conducted on a small sample of the crude reaction mixture
solution after running it through a miniature column that was composed of roughly 5 cm

of silica gel atop a cotton ball in a Pasteur pipet. Efforts to separate and purify the reaction
products from these reactions are still ongoing.
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CHAPTER VI

BIOLOGICAL ACTIVITY OF THE COBALT(II)
BIPYRIDYL/DIPHENYLAZODIOXIDE COMPLEX SALT IN CELL STUDIES

6.1 Rationale
In addition to its catalytic applications, we became interested in the investigation
of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 as a potential anticancer drug, since its unusual

trigonal prismatic coordination geometry suggested the possibility of its having novel
biological effects in addition to novel reactivity outside of living systems. As was
previously mentioned in Chapter I, Section 1.2, the use of transition metal complexes as

anticancer drugs is a crucial pharmaceutical application. Interestingly, besides vitamin B12

(cobalamin),171 there have not been any cobalt-based drugs in widespread clinical use.

However, as mentioned in Chapter I, Section 1.2, the cobalt(III) imine complex Doxovir
(CTC-96) has successfully completed phase II clinical trials in the treatment of herpes
simplex virus172 and phase I clinical trials in the treatment of two viral eye infections:
ophthalmic herpetic keratitis173 and adenoviral conjunctivitis174.175 Moreover, our interest

was to see if the presence of the azodioxide ligand would lead to a change in anticancer
effects, thus expanding the potential applications of azodioxide complexes. Prior to our
work, no biological studies of azodioxide complexes had been reported.
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6.2 Overview of Apoptosis
Apoptosis is a type of energy-dependent (requiring intracellular ATP)
“programmed” cell death that usually occurs during developmental and aging processes.176

Apoptosis occurs as both a homeostatic and a defense mechanism. As a homeostatic
mechanism, apoptosis can preserve cell populations. Apoptosis as a defense mechanism

can occur in immune reactions or when toxic agents damage cells.176,177 When a cell
undergoes apoptosis, the following structural characteristics or features of the cell are

noticeable: a decrease in cell size, a bulging plasma membrane, cell rounding, the
condensation of chromosomes, and the fragmentation of DNA. Additionally, apoptotic

bodies appear containing the undamaged organelles and cytoplasm within the plasma
membrane; these apoptotic bodies prevent cells undergoing apoptosis from releasing their
components into nearby tissue, which would lead to inflammation.176,178

In contrast to apoptosis, necrosis is an energy-independent (not requiring
intracellular ATP), uncontrolled form of cell death, also known as “accidental” cell death.

Necrosis is usually considered a harmful process in which the following characteristics or
features of a cell are noticeable: an increase in cell size, a disturbed plasma membrane,

damage to organelles, and the release of cell components into nearby tissue, leading to
inflammation. Necrosis usually occurs in cells as a result of extreme changes in
physiological conditions, which include (but are not limited to) hypoxia, hypoglycemia,
exposure to toxic substances, and extreme temperature changes. 176,179

6.2.1 Major Proteins Involved in Apoptosis
During apoptosis, a very large number of proteins are involved, regardless of the

pathway of apoptosis. (The different pathways of apoptosis will be discussed in the
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subsequent section.) Before explaining the major pathways of apoptosis, it is important to

provide some background information on some of the major apoptotic proteins.

Caspases: One major class of proteins that play critical roles in apoptotic pathways
is the caspases. These proteins are cysteine proteases that are targeted towards aspartate

residues. Caspases exist in cells in inactive forms known as procaspases.180 During
apoptosis, however, these procaspases are cleaved at particular internal aspartate residues
and thus become activated. The caspase family of proteins can be divided into two types:
initiator caspases and effector caspases. Examples of initiator caspases are caspase-2,

caspase-8, caspase-9, and caspase-10. Initiator caspases become activated (cleaved) once

a death signal (regardless of the pathway) is received. These caspases then lead to the
activation (cleavage) of effector caspases. Examples of effector caspases are caspase-3,
caspase-6, and caspase-7. These effector caspases cleave important proteins such as cell
cycle proteins, signal transduction proteins, and poly(ADP-ribose)polymerase (PARP).

The cleavage of these proteins by effector caspases then results in apoptosis.181
Bcl-2 Family: In addition to caspases, the Bcl-2 (B-cell lymphoma-2) family of

proteins play a major role in apoptosis. These proteins are primarily responsible for

regulating the intrinsic apoptotic pathway (see Section 6.2.2 for the distinction between the
intrinsic and extrinsic apoptotic pathways).182 The Bcl-2 family contains both pro-

apoptotic proteins as well as anti-apoptotic proteins. Two examples of pro-apoptotic

proteins in this family are Bim and BAD. Bim is responsible for interacting with Bcl-2
proteins with anti-apoptotic activity and those with pro-apoptotic activity, especially with
proteins Bax and Bak. The interaction of Bim with Bax and Bak results in conformational
changes that are required for the mitochondrial outer membrane permeabilization (MOMP)
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complex to form, which is a critical step in the intrinsic pathway of apoptosis. BAD is a

Bcl-2 binding protein that binds to anti-apoptotic protein members of the Bcl-2 family,
leading to their inactivation.182 An example of an important anti-apoptotic protein in the

Bcl-2 family is Bcl-2 (B-cell lymphoma protein-2) itself. The Bcl-2 protein inhibits the
activity of the pro-apoptotic protein members except for Bax and Bak.182
p53: Another important protein involved in apoptosis is p53, which is coded for by

a tumor suppressor gene. This protein is responsible for activating gene transcription in
genes whose products trigger apoptosis.183 For example, p53 can regulate the transcription
of the Bcl-2 family’s pro-apoptotic proteins by ensuring that there are more pro-apoptotic

proteins than anti-apoptotic proteins. Apoptosis that is mediated by p53 occurs mainly

through the intrinsic pathway, although the possibility of this type of apoptosis occurring
through the extrinsic pathway cannot be ruled out. The p53 protein is known for
contributing to apoptosis that is induced by chemotherapy.183
PARP: A major event that is considered a hallmark or a classical indicator of

apoptosis is the cleavage of the protein PARP. PARP is an enzyme with a molecular weight

of 116 kDa that is useful in DNA replication and in cellular emergencies such as in DNA
repair. During apoptosis, effector caspases cleave PARP into an 89 kDa C-terminal

fragment and a 24 kDa N-terminal fragment, inactivating the enzyme.184

6.2.2 Apoptotic Pathways
There are a wide variety of stimuli that cause apoptosis, but not all forms of
apoptotic cell death will occur in response to the same stimuli.176 There are two possible

pathways in which apoptosis can occur in a cell: the extrinsic, or death receptor, pathway
and the intrinsic, or mitochondrial, pathway. A general outline of these apoptotic pathways
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is shown in Figure 49.

Extrinsic Pathway: The extrinsic pathway starts out with death ligands (cell death
signals) binding to death receptors that belong to the tumor necrosis factor (TNF) family.
These death receptors then acquire an adaptor protein. The initiator procaspases

(procaspase-8 and procaspase-10) bind to the adaptor protein, resulting in the formation of

the death-inducing signaling complex (DISC). DISC then activates the procaspases to

caspase-8 and caspase-10. The effector procaspases (procaspase-3, procaspase-6, and
procaspase-7) then become activated to caspases, leading to protein cleavage and

ultimately apoptosis.185,186

Intrinsic Pathway: For the intrinsic pathway of apoptosis, stimuli such as damaged
DNA in cells, oncogene upregulation, excess Ca2+, and oxidants cause this pathway to
occur. These stimuli first lead to the upregulation of the pro-apoptotic proteins Bim and

BAD. Bim and BAD activate the pro-apoptotic proteins Bax and Bak, which, like Bim and

BAD, are members of the Bcl-2 family. Once Bax and Bak are activated, mitochondrial
outer membrane permeabilization (MOMP) occurs. This permeabilization leads to the

release of cytochrome c, which then leads to the apoptosome being formed from
cytochrome c, apoptotic protease-activating factor-1 (APAF-1), and procaspase-9. Within

the apoptosome, procaspase-9 is activated to its caspase form, which then leads to the

activation of effector procaspases (procaspase-3, procaspase-6, and procaspase-7), leading
to protein cleavage and ultimately apoptosis.185,187-189
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Figure 49: Extrinsic and Intrinsic Apoptotic Pathways.

6.3 Apoptosis in Cancer and Cancer Therapy
An important major role of apoptosis is cancer prevention. Therefore, the inhibition
of apoptosis is an important indication of cancer, and it is nonspecific to the cancer type or

cause of the cancer.185,187,190,191 There are many ways in which apoptosis is inhibited in
cancer cells. In many cases, however, the intrinsic pathway of apoptosis is inhibited,
through the upregulation of anti-apoptotic protein members of the Bcl-2 family. The
upregulation of these anti-apoptotic proteins is present in more than half of all cancers.
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Another important, albeit less common, way in which the intrinsic pathway of apoptosis is

inhibited is by the inhibition of caspase function after MOMP.185,190 There are a wide
variety of ways in which anti-apoptotic Bcl-2 proteins are upregulated and in which caspase
function is inhibited.

Regarding cancer therapy, the most successful non-surgical treatment of cancer is
the pharmaceutical targeting of apoptotic pathways. Different stages in both apoptotic

pathways (intrinsic and extrinsic) have been targeted by several anticancer drugs.185,192 Any

stage in either pathway can be a target for cancer treatment, and there is currently no
general consensus regarding which target is the most effective.185 However, since the

overexpression of anti-apoptotic Bcl-2 proteins occurs in many cancers, many apoptosis

targeting methods involve the suppression of anti-apoptotic Bcl-2 proteins and the
stimulation of pro-apoptotic Bcl-2 proteins.185,188

6.4 Cisplatin
Since my project focuses primarily on transition metal chemistry, I would like to

discuss as important background cisplatin, cis-Pt(NH3)2Cl2,193 an important example of a
transition metal complex that acts as an anticancer agent by inducing apoptosis. Cisplatin

is a neutral complex with platinum in the +2 oxidation state and a square-planar

coordination geometry, whose structure is shown in Figure 50. Cisplatin was the first
metal-based anticancer agent to reach global clinical use and remains today one of the most

successful anticancer drugs.175,194,195 Cisplatin can be used to treat a variety of different
types of cancer, including testicular, ovarian, head and neck, and cervical cancers.196
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nh3

h3n-- Pt—Cl
Cl
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Figure 50: Structure of cisplatin.
Cisplatin’s mechanism of action involves its interaction with DNA. Before cisplatin

can interact with DNA, it first needs to become activated by an aquation reaction, in which
cisplatin’s chloride (Cl-) ligands are replaced with water (H2O) ligands, becoming cis-

Pt(NH3)2(H2O)22+.197,198 Aquation usually takes place because of the high levels of water
in cells. The N-7 sites of the DNA purine bases guanine or adenine, which are labeled in

their structures shown in Figure 51, then displace the H2O ligands from cis-

Pt(NH3)2(H2O)22+, resulting in two portions of DNA becoming crosslinked to form
cisplatin-DNA adducts.197,199 The two types of crosslinking that can result are interstrand
and intrastrand. Interstrand crosslinking occurs where two strands of DNA are connected
by a Pt bridge. On the other hand, intrastrand crosslinking occurs where two purine bases

of the same DNA strand are connected by a Pt bridge, a process in which a kink is

introduced into the structure. The mechanism of action of cisplatin is very similar to that
of alkylating agents, which are organic anticancer drugs that use an alkyl group to crosslink
two purine bases of DNA rather than use a metal. Therefore, cisplatin is sometimes referred

to as a “nonclassical alkylating agent,” despite not actually containing any alkyl groups per

se. Once the cisplatin-DNA adducts are formed, many signal transduction pathways

become activated, which eventually lead to apoptosis.197,200
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Figure 51: Structures of guanine and adenine with their corresponding numerical schemes.
Even though cisplatin is a successful drug in cancer treatment, it causes adverse
effects in patients because of its high cytotoxicity. Some of those adverse effects include

kidney damage, liver damage, nervous system damage, and ear damage. In order to lower

cytotoxicity levels, further generations of Pt-containing drugs have been developed and are
either FDA-approved (e.g. carboplatin and oxaliplatin) or are currently in U.S. clinical
trials (e.g. satraplatin and lobaplatin).175,194,201 Importantly, since complexes of 2nd- and 3rd-

row transition metals are often more toxic than those of 1st-row transition metals,202 and
one important goal for metal-based drug development is reducing toxicity profiles,203 the

development of drugs containing 1st-row transition metals is desirable.

6.5 Background on Monometallic Cobalt(II) Complexes Shown to Induce Apoptosis
A variety of cobalt complexes, in which cobalt is either in the +2 or +3 oxidation

state, have been demonstrated to be cytotoxic against particular cancer cell lines that have

been reported to induce apoptosis.204 For better comparison with our complex salt
[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2, which is monometallic with Co in the +2 oxidation

state, I will give an overview of some examples of monometallic Co(II) complexes that
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have been shown to induce apoptosis in cancer cell lines. Klegeris and coworkers were
able to show that a series of square-planar Co(II) complexes containing p-ketoaminato
ligands increase caspase-3 activation and therefore induce apoptosis in prostate cancer

cells.204,205 Pombeiro and coworkers demonstrated that a series of Co(II) tris(pyrazolyl)methane (also known as scorpionate) complexes induce apoptosis in liver and colorectal

cancer cells. The mechanism of action for these scorpionate complexes was proposed to
involve the production of reactive oxygen species (ROS).204,206 Chiniforoshan and

coworkers were able to show that a Co(II) complex containing 1,10-phenanthroline and the
conjugate base of juglone (a natural product) as ligands induces apoptosis in colorectal,

cervical, and liver cancer cells. The induction of apoptosis was proposed to involve DNA
intercalation.204,207 Gao and coworkers demonstrated the ability of a Co(II) complex
containing the ligand tris(imidazolyl)benzene to induce apoptosis in oral epithelial

carcinoma cells through DNA fragmentation and intercalation.204,208 Simpson and
coworkers were able to show that a series of Co(II) complexes containing benzyl carbazatederived imines as ligands induce apoptosis in leukemia cells. Unfortunately, the

mechanism of action of these complexes was not determined.204,209 Chen and coworkers
reported a Co(II) complex with oxoisoaporphine ligands as inducing apoptosis in ovarian

cancer cells that happened to be resistant to cisplatin. Apoptosis induction involved an
increase in ROS levels and caspase-3 and caspase-9 activation.204,210 Filipovic and
coworkers were able to show that a Co(II) complex containing an O-donor ligand of the
(chalcogen)-semicarbazone type induces apoptosis in cervical cancer cells and in all-trans

retinoic acid-resistant acute myeloid leukemia cells. Apoptosis induction involved the
ROS-mediated damage of DNA.204,211
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6.6 Results and Discussion

The biological activity of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2, in addition to the

homoleptic [Co{Ph(O)NN(O)Ph}4](PF6)2, was studied, with the results published in ACS
Omega204 in collaboration with Prof. Aimin Zhou of Cleveland State University and his
former Ph.D. students, Drs. Norah Alghamdi and Ruhan Wei.

In this collaboration, we learned that [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 induced
apoptosis in SK-HEP-1 human liver adenocarcinoma cells. These cells were treated with

or without varying concentrations of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 in DMSO for 12
hours, where DMSO was used as a vehicle to overcome the limited solubility of

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 in water. It is important to note here that UV-visible

experiments confirmed good stability of 10 uM [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 in
DMSO over a period of at least one week when storing the solution in a dark place at room
temperature.

Figure

52

shows

that

as

the

concentration

of

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 increases, the cells become rounder and the number of
viable cells decreases, meaning that higher concentrations have a greater apoptotic effect

on the cells.204
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Figure 52: Cell morphology after 12 hour treatment with or without various
[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 concentrations in DMSO. The control represents cells
without any treatment. The DMSO morphology represents cells treated with only DMSO.
For each well, images were taken under 20* magnification from five different fields at
random using an inverted phase-contrast fluorescence microscope (Carl Zeiss).204
Furthermore, flow cytometry was performed on the SK-HEP-1 cells after they were
treated with 10 ^M [Co(bpy){Ph(O)NN(O)Ph}?](PF6)2 for 12 hours in relation to the
control. Figure 53 shows the flow cytometry results.204 An Annexin V fluorescein

isothiocyanate (FITC)/propidium iodide (PI) apoptosis detection kit was used for flow
cytometry experiments. In Figure 53, the first quadrant (Q1) represents necrotic cells, in

which only PI stains these cells (Annexin V-FITC-/PI+); quadrant 2 (Q2) represents late
apoptotic cells, in which both Annexin V-FITC and PI stain these cells (Annexin V-

FITC+/PI+); quadrant 3 (Q3) represents viable cells, in which neither Annexin V-FITC nor
PI stain these cells (Annexin V-FITC-/PI-); and quadrant 4 (Q4) represents early apoptotic

cells, in which only Annexin V-FITC stains these cells (Annexin V-FITC+/PI-).212 As
Figure 53 shows, the percentage of cells that died from apoptosis was greatly increased
111

from 4.8 to 16.6% after treatment with [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2, indicating that

cell death occurs primarily by apoptosis as opposed to necrosis. It is important to note that
[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 is not capable of fluorescence; attempts to perform

fluorescence spectroscopy on this compound did not yield emission spectra. Therefore, no
fluorescence from this complex interfered with the flow cytometry results.204

Control

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2

Figure
53:
Flow
cytometry
results
after treatment
with
10 ^M
[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 for 12 hours. In a dark environment at 4°C, each
sample was stained with 5 ^L of Annexin V-FITC and 5 ^L of PI for 15 minutes and 400
^L of 1x binding buffer was added. Using a flow cytometer with BD FACSDiva software,
the cells were analyzed.204 Annexin V-FITC-/PI- cells were determined as being viable,
Annexin V-FITC+/PI- cells were identified as being early apoptotic. Annexin V-FITC+/PI+
cells were determined as being late apoptotic. Annexin V-FITC-/PI+ cells were identified
as being necrotic.212
In addition to flow cytometry, Western blot analysis was also performed204 in order

to investigate the mechanism of apoptosis in the SK-HEP-1 cells caused by

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2. Western blot analysis revealed that apoptosis in these

cells involved the cleavage of PARP, which is a hallmark of apoptosis,184 the activation

(by cleavage) of procaspases (caspase-8 and caspase-9), the upregulation of pro-apoptotic
proteins (BAD and Bim), and the downregulation of anti-apoptotic proteins (Bcl-2). The
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involvement of these species in apoptosis in a concentration- and time-dependent manner
is depicted as a Western blot analysis204 in Figure 54. For the concentration-dependent

studies, the [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 concentration ranged from 0-10 uM, with
the cells being treated with each concentration for 12 hours. For the time-dependent studies,
the cells were incubated with 2 uM [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 for times ranging

from 1-36 hours. In both concentration- and time-dependent studies, the results suggest
apoptosis is induced through both the extrinsic and intrinsic pathways, with the extrinsic

pathway of apoptosis being more favorable over the intrinsic pathway.204 This conclusion
is based on the greater expression of cleaved caspase-8, which is involved in the extrinsic

pathway,185,186 than that of cleaved caspase-9, which is involved in the intrinsic
pathway.185,187-189
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Figure 54:
Concentration- and time-dependent protein levels after treating cells with
[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2. The preparation of total protein extracts involved
suspending cell pellets in Triton-X 100 lysis buffer, which is composed of 50 mM N-(2hydroxyethyl)piperazine-N'-ethanesulfonic acid, 150 mM NaCl, 1% Tris-X 100, and 5 mM
ethylenediaminetetraacetic acid. The lysate mixture was then centrifuged at 20000g in a
microcentrifuge for 10 minutes at 4°C. A Shimadzu UV-1280 UV-visible spectrometer
was then used to measure the total protein content in the supernatant. The same amount of
protein from each sample underwent 10% SDS-PAGE. The proteins were then transferred
to a poly(vinylidene difluoride) membrane at a voltage of 100 for 80 minutes. Once the
membrane was transferred, it was incubated for 1 hour at 25°C with 5% nonfat milk in
TBST buffer, which is composed of 1 mM Tris at pH 7.4, 150 mM NaCl, and 0.2% Tween20. The membrane was then incubated overnight at 4°C with a primary antibody in TBST.
After washing the membrane with TBST several times, the membrane was incubated with
a horseradish peroxidase-linked secondary antibody that was diluted 1:3000 and then
washed three times with TBST. The membrane was processed using a Thermo Fisher
Scientific Pierce ECL Plus Western Blotting Substrate by obtaining an enhanced
chemiluminescence signal. GAPDH was used as a housekeeping protein or loading
control.204
Moreover, since some Co(II) species are known for inducing apoptosis via the

generation of ROS and oxidative DNA damage, akin to the iron(II)-catalyzed Fenton

reactions204,213 (in which Fe2+ catalyzes the production of OH' from H2O2214), we were
interested in determining whether or not ROS were involved in the apoptosis mechanism
of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2. This assay involved treating the SK-HEP-1 cells
with different concentrations of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 for 14 hours and then

running a fluorescence-based ROS assay that particularly measures the levels of the
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hydroxyl radical and superoxide, which are types of ROS. These assays showed that ROS
levels greatly increased at high concentrations of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2, but
only modestly increased at the concentrations used in the flow cytometry and Western blot

experiments. These results suggest that ROS-mediated DNA damage is not likely the main
mechanism of apoptosis induced by [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2, though it cannot

be ruled out entirely from making some contribution to apoptosis. These results are
presented in Figure 55.204

Figure 55: Effect of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 on ROS levels in SK-HEP-1 cells.
The preparation of the master reaction mix followed the provided protocol by SigmaAldrich, and 100 ^L of this mixture was added to each well. The cells were incubated with
this mixture for 1 hour and were then treated with the different concentrations of
[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 with PBS buffer. The cells then underwent further
incubation for 14 hours. With the use of a Hitachi F-7000 fluorescence spectrometer, the
fluorescence intensity was measured using an excitation wavelength of 490 nm. The
emission spectra showed an emission peak at 525 nm. Each treatment was conducted with
16 replicates.204
In order to assess the cytotoxicity of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 to SK-

HEP-1 cells, a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
assay was conducted. The cells were incubated with [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 at
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a series of concentrations ranging from 5.12 nM to 2 mM for 48 hours before the assay was
performed. Interestingly, the results of the MTT assay revealed a substantial loss in cell

viability only at the higher [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 concentrations of 400 uM
and 2 mM, which are higher concentrations than those shown to induce apoptosis by our
phase-contrast microscopy, flow cytometry, and Western blot experiments.204 However,
there has been evidence for MTT assays underestimating cytotoxicity and overestimating

cell viability.215 This may explain the inconsistency between our MTT results and the

results from our other experiments.204
In addition to SK-HEP-1, other cell lines were treated with concentrations of

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 at 2 pM and 10 pM for 12 hours to see if it could induce
apoptosis in more than one cell line. The other cell lines that were tested were HEK 293
(human embryonic kidney cells), HT-29 (colon cancer), MCF-7 (breast cancer), and PC-3

(prostate cancer). However, [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 did not cause substantial
PARP cleavage in these lines as it did in SK-HEP-1 cells, suggesting that

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 is selective.204 (See Figure 56.) The selectivity of
[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 is encouraging and suggests that potential therapeutic

use of this compound against liver cancer cells may largely spare cells in other organs.
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Figure 56: Effect of 2 ^M and 10 ^M of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 on PARP
cleavage in (a) HEK 293 cells (b) HT-29 cells (c ) MCF-7 cells (d) PC-3 cells after 12
hours.204 See Figure 54 and Section 6.7.4 on how the Western blot analysis was conducted.
As an additional set of control experiments, we investigated the ability of the

starting materials used in the synthesis of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 to induce
apoptosis in SK-HEP-1 cells independently. The starting materials that were analyzed were

Co(bpy)Cl2216,217 and PhNO. (Refer to Chapter III, Section 3.2 for details on the synthesis
of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2.) Additionally, the Co(II) complex Co(phen)Cl2218
(phen = 1,10-phenanthroline), a structurally similar compound to Co(bpy)Cl2, and CoCl2,

a salt that dissociates to Co2+ and Cl- ions in aqueous solution, were also analyzed. It is
important to note that the free (uncoordinated) azodioxide ligand Ph(O)NN(O)Ph was not
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analyzed in this set of control experiments because free Ph(O)NN(O)Ph exists
predominantly as a monomeric nitrosoarene, PhNO, in the solution phase, whereas dimeric

azodioxides are generally favored in the solid phase.219,220 SK-HEP-1 cells were treated

with each of these four compounds at 10 ^M for 12 hours. None of these compounds

triggered

substantial

PARP

cleavage

in

SK-HEP-1

cells

as

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 did. (See Figure 57.) These results indicate that Co

without azodioxide is not responsible for the induction of apoptosis, either by itself as

aquated Co2+ or as part of a complex with aromatic diimine ligands. Therefore, we propose
that the azodioxide ligand Ph(O)NN(O)Ph is critical to the biological activity of

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2.204
[Co{Ph(O)NN(O)Ph}4](PF6)2

showed

the

homoleptic

complex

salt

similar

apoptotic

activity

to

Importantly,
very

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 in SK-HEP-1 cells,204 which further supports our

conclusion that the Ph(O)NN(O)Ph ligand plays an important role in the biological activity.

Figure 57: Effect of 10 ^M of starting materials and CoCh and Co(phen)Ch on cleavage
of PARP in SK-HEP-1 after 12 hours.204 See Figure 54 and Section 6.7.4 on how the
Western blot analysis was conducted.
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6.7 Experimental Methods

6.7.1 Reagents and Antibodies
The preparations of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 and Co(bpy)Cl2216 are
detailed in Chapter III of this dissertation and in our synthesis and characterization

publication in ACS Omega.217 The Co(II) complex Co(phen)Cl2 was prepared following a
procedure reported by Siddiqi and coworkers.218 The antibodies used for procaspase-8,

cleaved caspase-8, procaspase-9, cleaved caspase-9, Bcl-2, Bim, BAD, and PARP were
obtained from Cell Signaling Technology, Inc. The antibody used for GAPDH was
obtained from Santa Cruz Biotechnology.204

6.7.2 Cell Culture and Treatment
All cancer cell lines used for our studies were grown in RPMI-1640, which was
obtained from Cleveland Clinic Foundation Core Facility, supplemented with 10% cosmic

calf serum and 1% antibiotics. Cells were stored at 37°C in a humidified atmosphere with
5%

CO2.

Cells

were

treated

with

or

without

varying

concentrations

of

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 for a given time frame once cell confluence reached

70%. Before being diluted in aqueous solution, [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 was

dissolved in DMSO.204
6.7.3 Apoptotic Cell Morphology

An inverted phase-contrast fluorescence microscope (Carl Zeiss) was used to
analyze all morphological changes in SK-HEP-1 cells after treating them with

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2. These cells were seeded into 6-well plates (12 x 104
cells/well), cultured to the appropriate confluence, and treated for 12 hours at 37°C with

relevant concentrations of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2. After the cells were treated,
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they were washed with phosphate-buffered saline (PBS). For each well, images were taken
under 20x magnification from five different fields at random.204

6.7.4 Western Blot
After SK-HEP-1 cells were treated, they were first washed with cold PBS twice
and then collected with a scraper. The preparation of total protein extracts involved

suspending cell pellets in Triton-X 100 lysis buffer, which is composed of 50 mM N-(2-

hydroxyethyl)piperazine-N'-ethanesulfonic acid, 150 mM NaCl, 1% Tris-X 100, and 5 mM
ethylenediaminetetraacetic acid. The lysate mixture was then centrifuged at 20000g in a

microcentrifuge for 10 minutes at 4°C. A Shimadzu UV-1280 UV-visible spectrometer

was then used to measure the total protein content in the supernatant. The same amount of
protein from each sample underwent 10% SDS-PAGE (sodium dodecyl sulfate

polyacrylamide gel electrophoresis). The proteins were then transferred to a
poly(vinylidene difluoride) membrane with the use of a Bio-Rad Mini-PROTEAN 3 wet
transfer unit at a voltage of 100 for 80 minutes. Once the membrane was transferred, it was

incubated for 1 hour at 25°C with 5% nonfat milk in TBST buffer, which is composed of

1 mM Tris at pH 7.4, 150 mM NaCl, and 0.2% Tween-20. The membrane was then
incubated overnight at 4°C with a primary antibody in TBST. After washing the membrane

with TBST several times, the membrane was incubated with a horseradish peroxidase-

linked secondary antibody that was diluted 1:3000 and then washed three times with TBST.

Finally, the membrane was processed using a Thermo Fisher Scientific Pierce ECL Plus
Western Blotting Substrate by obtaining an enhanced chemiluminescence signal.204

120

6.7.5 Flow Cytometry
A BD Biosciences Annexin V fluorescein isothiocyanate (FITC)/propidium iodide
(PI) apoptosis detection kit was used. After the SK-HEP-1 cells were treated with

[Co(bpy){Ph(O)NN(O)Ph}2](PF6)2, they were collected in cold PBS, centrifuged for 5 min

at 4°C at a speed of 1500g, washed with PBS twice, and resuspended in 100 pL of 1x
binding buffer per sample. In a dark environment at 4°C, each sample was stained with 5

pL of Annexin V-FITC and 5 pL of PI for 15 minutes and 400 pL of 1x binding buffer was
added. Using a flow cytometer with BD FACSDiva software, the cells were analyzed.204
Annexin V-FITC-/PI- cells were determined as being viable, Annexin V-FITC+/PI- cells

were identified as being early apoptotic. Annexin V-FITC+/PI+ cells were determined as

being late apoptotic. Annexin V-FITC-/PI+ cells were identified as being necrotic.212
Fluorescence spectroscopy of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 was performed using a

Hitachi F-7000 fluorescence spectrometer.204
6.7.6 ROS Assay
A Sigma-Aldrich fluorometric intracellular ROS kit was used to assess any
production of ROS while cells were being treated with [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2.

Before the assay was performed, cells were grown in medium in a 96-well plate at 4000
cells/well overnight. The preparation of the master reaction mix followed the provided
protocol by Sigma-Aldrich, and 100 pL of this mixture was added to each well. The cells

were incubated with this mixture for 1 hour and were then treated with the different

concentrations of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 with PBS buffer. The cells then
underwent further incubation for 14 hours. Finally, with the use of a Hitachi F-7000

fluorescence spectrometer, the fluorescence intensity was measured using an excitation
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wavelength of 490 nm. The emission spectra showed an emission peak at 525 nm. Each

treatment was conducted with 16 replicates.204

6.7.7 MTT Assay

In a 96-well plate at 3000 cells/well, SK-HEP-1 cells were grown in the medium
overnight. The relevant [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 concentrations replaced the
growth medium so that the cells could incubate for 48 hours. A 1:3 ratio of 5 mg/mL MTT
and growth medium was prepared as the MTT solution, and 100 uL of this solution was

added to each of the wells. The cells were then further incubated for 2 to 4 hours and then
200 uL DMSO was added to each of the wells. The absorbance at 570 nm was measured

as soon as the precipitates had dissolved. A total of 8 replicates were conducted for each

treatment.204
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CHAPTER VII

FUTURE DIRECTIONS

7.1 Catalysis
Since the isolated yields and the turnover numbers reported for our catalysis

experiments for the direct allylic amination/C-C double-bond transposition reactions are
thus far low221 (see Figure 29 in Chapter V, Section 5.3.1), one future goal is to improve
the yield and scope of these reactions by modifying our [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2

catalyst,221 by preparing analogous catalysts containing substituted azodioxide ligands,
which would include those with electron-donating and/or electron-withdrawing
substituents on their aromatic rings. The synthesis of these types of azodioxide complexes

with variable substituents on their ligands has the potential to enable a high degree of

“tuning” of catalyst structure to enhance catalytic performance. It will also be interesting
and informative to investigate and compare the catalytic ability of other azodioxide

complexes prepared by our group in the future in direct allylic amination reactions.
Since only preliminary GC-MS results have thus far been obtained for our

experiments on the catalysis of nucleophilic allylic substitution reactions (see Chapter V,
Section 5.3.2), an ongoing effort will be to optimize reaction conditions. Optimizing
reaction conditions may help reduce the presence of unreacted substrate molecules in the
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synthesis of the allylic amine drug cinnarizine after the reaction is complete222 and improve
the yields of nucleophilic allylic substitution reactions involving simpler substrates. Also,
our efforts of purifying the desired allylic amine products (detected by GC-MS) from

nucleophilic allylic substitution are ongoing. Once these allylic amines are purified and
their syntheses are confirmed by NMR spectroscopy, we can then report with confidence
that [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 is an active catalyst for two types of allylic

amination reactions, hence expanding its catalytic applications.
Additional future work can involve studying the catalytic behaviors of the

homoleptic complex salt [Co{Ph(O)NN(O)Ph}4](PF6)2, prepared by former Boyd group
Ph.D. student Dr. Lakshmi Balaraman, and other azodioxide complexes prepared by our
group in the future, in the synthesis of allylic amine drugs and comparing their catalytic

behaviors to that of [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2. If further studies show evidence
that [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 and our other azodioxide complexes can act as

competent catalysts in the one-pot synthesis of cinnarizine,222 and possibly in the synthesis
of other allylic amine drugs, this will mean that [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 and

other azodioxide complexes not only act as catalysts for different types of allylic amination,
but also have the potential to be useful catalysts in the industrial production of allylic amine
drugs.

7.2 Biological Studies
Future work in collaboration with Prof. Aimin Zhou and his students will involve
investigating the therapeutic potential223 of both [Co(bpy){Ph(O)NN(O)Ph}2](PF6)2 and

[Co{Ph(O)NN(O)Ph}4](PF6)2 in cancer through the use of liver cancer mouse models, as

well as additional cellular studies to further elucidate the mechanism of their pro-apoptotic
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behavior. Additionally, future work will involve studying the interactions of both Co
azodioxide species, both homoleptic and heteroleptic, with SK-HEP-1 cells as well as with

other cell lines in order to explain the selectivity of these species to induce apoptosis in
only SK-HEP-1 cells. Further stability studies on both Co azodioxide species will be

conducted to gain more insight about their structural integrities as cells are being treated
with them. It would also be interesting to study the potential antiviral activity of both Co

azodioxide species, since the Co-containing species Doxovir224 has shown to be a

promising candidate as an antiviral agent. Another future goal is to study the potential
biological activity of other azodioxide complexes prepared by our group in the future, with
an eye toward identifying pro-apoptotic activity in SK-HEP-1 cells and other cell lines.223

Biological studies on future azodioxide complexes will enable the construction of
structure-activity relationships in which metals and ancillary ligands, as well as
substituents on azodioxide ligands, can be varied in order to optimize biological activity.
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